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(mTOR) is a serine-threonine kinase that controls several
important aspects ofmammalian cell function.mTORactivity
is modulated by various intra- and extracellular factors; in
turn, mTOR changes rates of translation, transcription, pro-
tein degradation, cell signaling, metabolism, and cytoskele-
ton dynamics. mTOR has been repeatedly shown to
participate in neuronal development and the proper function-
ing of mature neurons. Changes in mTOR activity are often
observed in nervous system diseases, including genetic dis-
eases (e.g., tuberous sclerosis complex, Pten-related syn-
dromes, neurofibromatosis, and Fragile X syndrome),
epilepsy, brain tumors, and neurodegenerative disorders
(Alzheimer’s disease, Parkinson’s disease, and Huntington’s
disease). Neuroscientists only recently began deciphering
the molecular processes that are downstream of mTOR that
participate in proper function of the nervous system. As a
result, we are gaining knowledge about the ways in which
aberrant changes in mTOR activity lead to various nervous
system diseases. In this review, we provide a comprehensive
view of mTOR in the nervous system, with a special focus on
the neuronal functions of mTOR (e.g., control of translation,
transcription, and autophagy) that likely underlie the contri-
bution of mTOR to nervous system diseases.  2016 The
Authors. Published by Elsevier Ltd on behalf of IBRO. This
is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Key words: mTOR, neuronal development, neuronal plastic-
ity, CNS disease, rapamycin.http://dx.doi.org/10.1016/j.neuroscience.2016.11.017
0306-4522/ 2016 The Authors. Published by Elsevier Ltd on behalf of IBRO.
This is an open access article under the CC BY-NC-ND license (http://creativecomm
*Corresponding author. Address: International Institute of Molecular
and Cell Biology, 4 Ks. Trojdena Street, Warsaw 02-109, Poland.
E-mail address: jaworski@iimcb.gov.pl (J. Jaworski).
Abbreviations: 4E-BPs, 4E-binding proteins; Atg13, autophagy-related
protein 13; BDNF, brain-derived neurotrophic factor; CGG,
trinucleotide; EGF, epidermal growth factor; FXS, Fragile X
syndrome; Hif1a, hypoxia-inducible factor 1-a; LTD, long-term
depression; LTP, long-term potentiation; MAMs, mitochondrion-
associated membranes; mTOR, mammalian/mechanistic target of
rapamycin; NSC, neural stem cell; p70S6K1, p70 ribosomal S6
protein kinase 1; PKC, protein kinase C; Rheb, Ras homolog
enriched in brain protein; SVZ, subventricular zone; Tsc, Tuberous
Sclerosis Complex; ULK1, unc-51-like kinase 1.
112Introduction 112Contents
mtor and its signaling network 113
mTOR complexes 113
Regulation of mTORCs 113
Canonical pathways of mTORC1 activation by
extracellular signals 113
mTORC1 activation by amino acids 114
Regulation of mTORC2 115
Downstream effectors of mTORCs 115
Translation 116
Protein degradation 117
Transcription and RNA processing 117
Cytoskeleton 118
Additional functions of mTORCs 118
Contribution of mtor to nervous system development
and physiology 118
Role of mTORC1 in neurodevelopment in vivo 119
Role of mTORC2 in the nervous system 120
mtor-related diseases of the nervous system 121
Genetic diseases 121
Tuberous sclerosis complex 121
PTEN hamartoma tumor syndrome and Proteus
syndrome 123
Malformations of cortical development 124
Neurofibromatosis 125
Fragile X syndrome 126
Down syndrome 126
Neurodegenerative disorders 126
Non-syndromic/cryptogenic epilepsy 127
Molecular basis of mTOR-related neuropathologies 128
Protein translation 128
Autophagy 128
Transcription and other cellular processes 129
Conclusions 130
Competing interests 130
Acknowledgments 130
References 130
Appendix A 139
Table A.1. Animal models of selected mTOR-related
diseases 139
INTRODUCTION
Mammalian/mechanistic target of rapamycin (mTOR) is a
serine-threonine kinase that controls several important
aspects of mammalian cell function (Malik et al., 2013b).
Its activity is modulated by various intra- and extracellular
factors, and the task of mTOR is to check whether intra-
cellular resources and the health of the cell are suﬃcient
to respond to extracellular stimuli. In the early 2000s,ons.org/licenses/by-nc-nd/4.0/).
K. Switon et al. / Neuroscience 341 (2017) 112–153 113when neuroscientists’ interest in mTOR began, very few
mTOR targets were known and conﬁrmed in mammals.
The most studied targets at the time were p70 ribosomal
S6 protein kinase 1 (p70S6K1) and eukaryotic initiation
factor 4E-binding proteins (4E-BPs). The major focus
was on the initiation of translation by mTOR (Burnett
et al., 1998). A widely accepted notion was that mTOR
allows an increase in the rate of translation in response
to extracellular stimuli. Long-term synaptic plasticity,
learning, and memory rely on de novo protein synthesis.
Therefore, mTOR took center stage in molecular studies
of neuronal plasticity. Consequently, mTOR was shown
to be critical for such forms of neuronal plasticity as
long-term potentiation (LTP), long-term depression
(LTD) and learning and memory (Jaworski and Sheng,
2006; Swiech et al., 2008). Soon afterward, mTOR was
proven to be critical for neuronal survival, diﬀerentiation,
and morphogenesis. The list of its known neuronal func-
tions is expanding every year. Changes in mTOR activity
began to be correlated with such neurological symptoms
as epilepsy, mental retardation, autism, and brain tumors
(Swiech et al., 2008; Garelick and Kennedy, 2011; Lipton
and Sahin, 2014; Bockaert and Marin, 2015).
The list of physiological states and neuropathologies
that are linked to mTOR grew very fast, but a
comprehensive understanding of mTOR regulation and
its cellular eﬀectors in neurons was lagging. With the
advent of transcriptomics, proteomics, and new imaging
technologies, our understanding of the importance of
mTOR and its cellular functions greatly expanded.
Changes in mTOR activity are now known to result in
increases in translation, transcription, autophagy, cell
signaling, metabolism and modiﬁcations in cytoskeleton
dynamics (Malik et al., 2013b). This review focuses on (i)
new developments in downstream mTOR processes that
are relevant to neuronal function,
(ii) newly identiﬁed neuronal func-
tions of mTOR complexes 1 and 2
(mTORC1 and mTORC2), and (iii)
diseases that are associated with
mTOR dysregulation and their
underlying molecular mechanisms.Fig. 1. mTOR and its protein complexes. (A) Protein domain composition of mTOR. HEAT –
huntingtin, elongation factor 3, regulatory subunit A of PP2A, TOR1 domain, FAT – FRAP, ATM,
TTRAP domain, FRB – FKBP12-rapamycin-binding domain, FATC – C-terminal domain, FKBP12 –
FK506-binding protein of 12 kDa. (B) Protein composition of mTOR complexes. mTOR forms two
protein complexes mTORC1 and mTORC2, which have diﬀerent protein composition and non-
overlapping sets of cellular substrates. See text for more details.mTOR AND ITS SIGNALING
NETWORK
mTOR complexes
mTOR is a large multidomain
protein that exists in two distinct
multiprotein complexes: mTORC1
and mTORC2 (Hay and
Sonenberg, 2004; Bhaskar and
Hay, 2007; Malik et al., 2013b;
Fig. 1). Proteins that are present
in both complexes include mTOR
protein itself, mammalian lethal
with SEC13 protein 8 (mLST8),
DEP domain-containing mTOR-
interacting protein (Deptor), Tel
two-interacting protein 1 (Tti1),
and telomere maintenance 2(Tel2; Sarbassov et al., 2004; Peterson et al., 2009;
Kaizuka et al., 2010). Speciﬁc to mTORC1 is regulatory-
associated protein of mTOR (Raptor) and proline-rich
AKT1 substrate 40 kDa (PRAS40; Kim et al., 2002;
Sancak et al., 2007; Vander Haar et al., 2007). mTORC2
contains rapamycin-insensitive companion of mTOR (Ric-
tor), mammalian stress-activated protein kinase-
interacting protein 1 (mSin1), and protein observed with
Rictor (Protor; Sarbassov et al., 2004; Frias et al., 2006;
Pearce et al., 2007). FK506-binding protein (FKPB12) is
a nonobligate mTOR-interacting protein that inhibits
mTORC1 activity by blocking the catalytic domain of
mTOR in the presence of the drug rapamycin (Jacinto
et al., 2004; Sarbassov et al., 2006). mTORC2 was initially
considered insensitive to rapamycin, but prolonged treat-
ment with rapamycin also inhibited this complex, perhaps
by sequestering mTOR kinase, which cannot form the
mTORC2 complex (Sarbassov et al., 2006). In recent
years, new insights into the exact structure of the
mTORC1 complex have been gained, thanks to advances
in cryo-electron microscopy. mTORC1 is an obligate
dimer, and its dimerization is necessary for its activity
and the phosphorylation of downstream targets (Yip
et al., 2010; Aylett et al., 2016). The dimerization of
mTORC1 complexes is regulated by newly characterized
WAC protein and the TTT (Tel2, TTI1, TT12)–Reptin/Pon-
tin complex (Kim et al., 2013; David-Morrison et al., 2016).Regulation of mTORCsCanonical pathways of mTORC1 activation by extra-
cellular signals. The activation of both mTOR complexes
requires the integration of speciﬁc signals, allowing the
proper orchestration of multiple cellular events, and it
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factors (Sengupta et al., 2010; Oh and Jacinto, 2011).
For mTORC1, the ﬁrst group includes the availability of
nutrients, especially amino acids, and the adenosine
monophosphate (AMP):adenosine triphosphate (ATP)
ratio, which reﬂects the energy state of the cell (Hahn-
Windgassen et al., 2005; Malik et al., 2013b; Bar-Peled
and Sabatini, 2014). Cellular stress (e.g., oxidative, geno-
toxic, and endoplasmic reticulum [ER] stress; Feng et al.,
2005; Sofer et al., 2005; Chen et al., 2011) and the inhibi-
tion of translation (Kimball et al., 2008) also aﬀect
mTORC1 activity. Recently, Christine Holt’s group pre-
sented evidence of the requirement of intact F-actin
dynamics for proper mTORC1 activation in response to
netrin-1 in axonal growth cones of tectal neurons (Piper
et al., 2015). Among the extracellular stimuli that are
important for the activation of both mTORCs in various
cell types are hormones (e.g., insulin), growth factors
(e.g., epidermal growth factor [EGF] and insulin-like
growth factor 1 [IGF1]), the extracellular matrix, and cell
adhesion molecules (Quevedo et al., 2002; Nomura
et al., 2003; Saucedo et al., 2003). In neurons, mTORC1
is also induced by neuron-speciﬁc stimuli, including brain-
derived neurotrophic factor (BDNF; Takei et al., 2004;
Skalecka et al., 2016), reelin (Jossin and Goﬃnet,
2007), netrin 1 (Piper et al., 2015), and several
neurotransmitters, including amino acids (e.g., glutamate,
c-aminobutyric acid [GABA]), monoamines (e.g., dopa-
mine, serotonin), acetylcholine, and neuropeptides (e.g.,
orexin; Lenz and Avruch, 2005; Schicknick et al., 2008;
Wang et al., 2014). In the case of glutamate, the activa-
tion of both ionotropic and metabotropic glutamate recep-
tors (mGluRs) induces mTORC1 (Cammalleri et al., 2003;
Hou and Klann, 2004; Lenz and Avruch, 2005; Macias
et al., 2013; Blazejczyk et al., 2016). Not all extracellular
signals activate mTOR in neurons. For example, the axo-
nal growth chemorepellent semaphorin 3A inhibits
mTORC1 activation via Tuberous Sclerosis Complex
(Tsc), which leads to growth cone collapse (Nie et al.,
2010). In contrast, glucocorticoids downregulate
mTORC1 in hypothalamic neurons (Shimizu et al., 2010).
The canonical pathway of mTORC1 activation by
trophic factors begins with the activation of their
respective receptor tyrosine kinases and downstream
signaling (e.g., phosphoinositide-30 kinase [PI3K]-Akt
and extracellular signal-regulated kinases [ERKs];
Fig. 2a; for review, see Malik et al., 2013b). Active Akt
and ERKs, in turn, phosphorylate and inactivate tuberin
(Tsc2), which together with hamartin (Tsc1) and TBC1D7
forms Tsc (Fig. 1; van Slegtenhorst et al., 1998; Inoki
et al., 2002; Dibble et al., 2012). Tsc2 acts as a guanosine
triphosphatase (GTPase)-activating protein (GAP) toward
Ras homolog enriched in brain protein (Rheb), a direct
activator of mTORC1 (Inoki et al., 2003a). Thus, the inac-
tivation of Rheb by Tsc leads to mTORC1 inhibition,
which is released by trophic factor-driven Akt activation
(Dan et al., 2002; Inoki et al., 2002; Manning et al., 2002).
Tsc2 can also be phosphorylated by other protein
kinases that prevent its inhibition by extracellular
stimulation (Fig. 2A). For example, Tsc2 is activated by
AMP-activated protein kinase (AMPK; Inoki et al.,2003b), which in turn is activated by low cell energy status
(signaled by an elevated AMP:ATP ratio). Thus, AMPK-
dependent Tsc2 phosphorylation should counterbalance
the eﬀect of trophic factors on mTORC1 if the energy sta-
tus of the cell is suboptimal. Indeed, in neurons, AMPK
activity prevents the BDNF-induced activation of
mTORC1 (Ishizuka et al., 2013).
Notably, Tsc is not the only heavily regulated node of
the mTOR signaling pathway. Some kinases that are
known to modulate Tsc2 also regulate mTORC1 directly.
For example, Akt phosphorylates and inactivates
PRAS40, an endogenous inhibitor of mTORC1 (Sancak
et al., 2007; Vander Haar et al., 2007). AMPK phosphory-
lates Raptor, leading to mTORC1 inactivation through
the binding of 14-3-3 protein to phospho-Raptor (Gwinn
et al., 2008). In contrast, the GSK3-dependent phosphory-
lation of Raptor is regulated by amino acid levels and
induces mTORC1 (Stretton et al., 2015). Lee et al.
(2009) found that mTORC1, under low-glucose condi-
tions, is inhibited as a result of Rheb sequestration by
the glycolytic enzyme glyceraldehyde 3-phosphate
dehydrogenase.
Activation of the classic mTORC1 pathway by trophic
factors, morphogens, and hormones is well studied. Much
less is known about the regulation of mTORC1 by
neurotransmitters. The canonical mechanism described
above is likely shared by some neurotransmitters (e.g.,
glutamate and opioids; Cammalleri et al., 2003; Lenz
and Avruch, 2005; Troca-Marı´n et al., 2011; Xu et al.,
2014). However, several examples suggest additional
means by which mTORC1 is regulated by neurotransmit-
ters. For example, Sucher et al. (2010) described the
direct binding of Rheb to the NR3A subunit of the N-
methyl-D-aspartate (NMDA) receptor. These authors
speculated that NR3A sequesters synaptic Rheb, leading
to mTORC1 inhibition. Orexin A stimulates mTORC1 in
an Akt- and Erk-independent manner. Instead, mTORC1
activation required orexin A-induced extracellular calcium
inﬂux and depended on the activity of lysosomal vacuolar
H+-ATPase (v-ATPase) and the small GTPase RagC
(Wang et al., 2014).mTORC1 activation by amino acids. The availability of
amino acids is another important regulator of mTORC1
activity (Fig. 2B). The levels of amino acids are sensed
by the Rag–Ragulator complex, which recruits mTORC1
to the lysosomal surface where it can be activated (for
review, see Zoncu et al., 2011). Amino acids also play a
role in regulating Tsc activity. The lack of amino acids
recruits Tsc to the lysosome via Rags, where it can inac-
tivate Rheb and disable the possibility of mTORC1 activa-
tion (Demetriades et al., 2014). The simultaneous
deprivation of amino acids, namely arginine, and growth
factors also leads to an increase in the localization of
Tsc to the lysosome, which is mediated by its interaction
with Rheb (Carroll et al., 2016). Additionally, the Akt-
dependent phosphorylation of Tsc causes it to dissociate
from the lysosome, so that it is no longer able to serve as
Rheb GAP (Menon et al., 2014).
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mTORC2 regulation are less well known. The best
characterized extracellular signals that activate
mTORC2 are growth factors and hormones that
upregulate PI3K activity (e.g., insulin and EGF; Huang
et al., 2008; Kumar et al., 2008). In yeast and cancer cells,
mTORC2 associated with the ribosome upon growth
factor stimulation, which was necessary for its activation
(Oh et al., 2010; Zinzalla et al., 2011). Additionally, in
the event of ER stress, GSK3b phosphorylates Rictor,
preventing mTORC2 from phosphorylating Akt. Such abalance between the activities of GSK3b and Akt allows
the cell to regulate glucose metabolism according to the
metabolic state of the cell (Chen et al., 2011). Recently,
Verma and Marchese (2015) described an additional level
of mTORC2 regulation by means of the degradation of
Deptor by the endosomal sorting complexes required for
transport (ESCRT), leading to mTORC2 activation. In
neuronal cells, mTORC2 is activated by neurotrophins,
glutamate, NMDA, and factors that induce LTP (Huang
et al., 2013).F
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3Downstream eﬀectors of
mTORCs. In recent years,
several studies, including large
phosphoproteomic screens,
revealed dozens of new potential
targets of mTORC1 and mTORC2
(Hsu et al., 2011; Yu et al., 2011;ig. 2. Regulators of mTOR activity. (A)
SC1/2-dependent and -independent
athways of mTORCs regulation by trophic
actors, glucose and cellular energy levels.
he canonical pathway of mTORC1 acti-
ation by trophic factors starts with the
ctivation of their respective receptor tyr-
sine kinases and subsequent increase in
I3K-Akt and ERK signaling. Akt and ERK
nactivate TSC complex, which is a major
nhibitor of mTORC1. However, when cel-
ular energy level is low TSC is activated by
MPK, what prevents response to trophic
actors. Some kinases can also regulate
TORC1 directly. Akt phosphorylates and
nactivates PRAS40, leading to mTORC1
ctivation. In contrast, AMPK phosphory-
ates Raptor, leading to mTORC1 inactiva-
ion. Trophic factors can also activate
TORC2 via PI3K. (B) mTORC1 regula-
ion by amino acids. The key component of
TORC1 regulation by amino acids is
ag–Ragulator complex. This complex
onsists of small Rag GTPases, which
orm heterodimers that contain RagA or
agB with RagC or RagD, and the Ragu-
ator complex, consisting of ﬁve proteins:
18, p14, MEK partner 1 (MP1), hepatitis B
irus X-interacting protein (HBXIP), and
7orf59. The RagA/B and RagC/D hetero-
imers are tethered to the cytoplasmic
urface of the lysosome by the Ragulator
caﬀold. In amino acid-starved cells,
agA/B binds GDP, and RagC/D binds
TP, and the complex is unable to recruit
TORC1 to the lysosome. Upon the addi-
ion of amino acids, the dimers change
heir nucleotide-binding state to RagA/B-
inding GTP and RagC/D-binding GDP.
his ‘‘active” dimer binds Raptor and
ecruits mTORC1 to the lysosomal surface
or subsequent activation by Rheb. The
agulator complex serves as a scaﬀold for
ag GTPases, but it also acts as a guanine
xchange factor (GEF) toward RagA and
agB. Ragulator senses amino acid avail-
bility via the activity of the V-ATPase and
ia the interaction with a newly discovered
ysosomal amino acid transporter,
LC38A9.
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numerous to be discussed herein in detail, but their identi-
ﬁcation demonstrated functions of mTORCs beyond the
control of translation initiation. In the following paragraphs,
we focus on the functions of mTOR that are most relevant
to neuronal physiology and pathology.Translation. Translation is an energy-consuming
process, and mammalian cells have generated
complicated mechanisms to control it, depending on
nutrient availability and the general condition of the cell.
mTOR kinase is the main factor that links the energy
state of the cell to protein translation. Canonical
regulation occurs at the level of translation initiation and
involves the phosphorylation of 4E-BP1 (Gingras et al.,
1999) and p70S6K1 (Burnett et al., 1998); Fig. 3A). The
eﬀects of mTOR-dependent phosphorylation of these
substrates were discussed elsewhere (e.g., Malik et al.,
2013b) and will not be described here. Aside from its
canonical roles in regulating cap-dependent translation,
mTORC1 mediates additional modes of translational con-
trol. For example, mTORC1 catalyzes the cap- and eIF-
4E-independent translation of IGF2 mRNA via the internal
ribosomal entry site (Dai et al., 2011).Fig. 3. mTOR targets and downstream cellular processes. (A) Translation
translation initiation acting on its best known substrates – 4E-BP1 and S6
Under nutrient-rich conditions, mTORC1 interacts via Raptor with the U
complex. Phosphorylation of ULK1 by mTORC1 prevents initiation of auto
acids level is low, mTORC1 is released from the ULK1–Atg13–FIP200 comp
promoted. Another way, by which autophagy is controlled by mTOR is the
AMBRA, a part of the Vps34-Beclin1 complex. mTOR-phosphorylated AM
from the complex that it forms with TRAF6, which weakens the progressio
Transcription. Several transcription factors (TFs) including MAF1, SREBP
were proven to be mTORC1 targets. Phosphorylation by mTOR in some cas
distribution of TFs (e.g., TFEB). (D) Cytoskeleton. mTORC1 controls intera
microtubules regulating interaction of its substrate CLIP-170 with an actin-bind
mTORC2 controls F-actin dynamics via PKCa and small GTPAse Rac1.Since the ﬁrst observation of ribosomes in axon
terminals (i.e., outside neuronal pericarion) by Bodian
(1965), neuroscientists have investigated the possibility
that proteins can be produced on demand locally at
synapses, which was eventually proven in the 1990s.
Tang et al. (2002) demonstrated the inﬂuence of mTOR
activity on local stimulus-driven, cap-dependent protein
synthesis in dendrites. In a subsequent study, Takei
et al. (2004) showed that the stimulation of hippocampal
neurons by BDNF in culture induced the synthesis of den-
dritic Arc (activity-regulated cytoskeleton-associated pro-
tein) and CamKIIa (Ca2+/calmodulin-dependent protein
kinase II). This process was inhibited by rapamycin. The
stimulation of NMDARs and mGluRs activates mTOR
and increases dendritic protein synthesis (Hou and
Klann, 2004; Gong et al., 2006), which contributes to
synaptic plasticity (Jaworski and Sheng, 2006; Swiech
et al., 2008).
Several follow-up studies focused on the local mTOR-
dependent translation of mRNAs. Schratt et al. (2004)
identiﬁed dozens of dendritic transcripts that are mTOR-
dependently associated with polysomes in response to
BDNF. Liao et al. (2007) then showed that upon BDNF
stimulation, several hundred proteins were upregulated
in synaptoneurosome preparations from cultured cortical. mTORC1 controls
K1. (B) Autophagy.
LK1–Atg13–FIP200
phagy. When amino
lex and autophagy is
phosphorylation of
BRA is sequestered
n of autophagy. (C)
1, HIF1a and TFEB
es regulates cellular
ction of F-actin and
ing protein IQGAP1.neurons. Among the transcripts that
are controlled by mTOR, some
encode proteins that inﬂuence neu-
ronal activity or the shape of dendritic
spines (e.g., CamKIIa, NR1, Homer2,
Limk2, GluA1, and GluA2), which
likely explains the way in which
mTOR-driven local translation con-
tributes to synaptic and structural
plasticity.
Despite the ﬁndings of local
translation upregulation by mTOR,
several studies indicate that a
certain pool of locally synthesized
proteins in neurons is suppressed by
mTOR activity. In the case of Kv1.1
ion channels, its dendritic synthesis
is repressed by active mTOR (Raab-
Graham et al., 2006) via miR-129.
When mTOR is rendered inactive,
the RNA-binding protein HuD pro-
motes Kv1.1 translation in dendrites
(Sosanya et al., 2013). Thus, mTOR
activity may upregulate the translation
of a large pool of synaptic mRNA via
4E-BPs and S6K, but it suppresses
another pool of mRNA via alternative
mechanisms, such as miRNAs.
Altogether, mTOR activity appears to
regulate the local translation of
transcripts that increase neuronal
excitability, promote late LTP
(L-LTP), and diminish mGluR-LTD.
Unclear is the way in which the sup-
pression of Kv1.1 translation at the
synapse ﬁts into this picture, although
K. Switon et al. / Neuroscience 341 (2017) 112–153 117diminished Kv1.1 expression has been suggested to
increase synaptic excitability (Raab-Graham et al.,
2006; Kepert and Kiebler, 2013).
Local protein synthesis that is controlled by mTOR
also contributes to neuronal development. mTOR and
p70S6K are needed for the local translation of Tau and
CRMP2 proteins, which both participate in neuronal
polarization (Morita and Sobue, 2009). Work by the Holt
group has shown that mTOR-dependent local translation
that occurs in navigating axonal growth cones is needed
for the proper response to chemoattractants and
chemorepellents (Piper et al., 2006, 2015). The require-
ment for mTOR-dependent local translation in axonal
growth cones is not restricted to development. mTOR
activation is induced by nerve injury, and the local produc-
tion of syntaxin-13 was shown to play an instrumental role
in the regenerative process (Cho et al., 2014). Local pro-
tein synthesis is also involved in dendritogenesis (Lee
et al., 2003; Vessey et al., 2008, 2010; Perycz et al.,
2011). Jaworski et al. (2005) demonstrated that mTOR
activity is necessary for proper dendritic arborization in
response to the activation of BDNF-PI3K-mTOR signaling
and identiﬁed S6K1 and 4E-BP1 as potential downstream
eﬀectors. Nevertheless, direct evidence of the involve-
ment of mTOR-dependent local translation in dendritoge-
nesis awaits direct veriﬁcation.Protein degradation. Macroautophagy, commonly
referred to as autophagy, allows the clearance of
obsolete proteins, misfolded or overexpressed protein
aggregates, and whole organelles. Autophagy begins
with the envelopment of a portion of the cytoplasm that
is destined for degradation with a double-membrane
vesicle called an autophagosome. The autophagosome
then undergoes fusion with the lysosome, and its cargo
is degraded. The resulting amino acids are reused in
metabolic processes (Levine and Klionsky, 2004). The
ﬁrst link between TOR kinase and autophagy was found
in yeast by Noda and Ohsumi (1998), who demonstrated
that rapamycin induces autophagy in S. cerevisiae.
mTORC1 activity negatively controls the initiation of
autophagy, and mTORC1 inhibition with either rapamycin
or amino acid starvation stimulates this process. A better
understanding of the molecular aspects of the involve-
ment of mTOR kinase in autophagy was achieved only
very recently when several mTORC1 substrates that are
involved in this process were identiﬁed (e.g., the unc-51-
like kinase 1 [ULK1]–autophagy-related protein 13
[Atg13]–FAK family kinase-interacting protein of
200 kDa [FIP200] complex and autophagy/Beclin-1 regu-
lator 1 [AMBRA]) (Ganley et al., 2009; Hosokawa et al.,
2009; Jung et al., 2009); Fig. 3B).
The basal level of autophagy is barely detectable in
neuronal cells under nutrient-rich conditions (Mizushima
et al., 2004). However, blocking the ﬁnal steps of autop-
hagic clearance leads to the rapid accumulation of
autophagosomes, suggesting that autophagy in neurons
occurs very eﬃciently (Boland et al., 2008). Live cell
imaging of cultured dorsal root ganglion and hippocampal
neurons revealed that autophagy in neuronal cells occurs
constitutively and in a precisely organized manner.Autophagosomes are continuously generated at neurite
tips and later transported toward the cell body while simul-
taneously undergoing maturation (Maday et al., 2012;
Maday and Holzbaur, 2014). Accumulating evidence indi-
cates that autophagy contributes to neuronal develop-
ment and neuroplasticity. Rapamycin treatment in
mouse neuroblastoma cells led to autophagy-dependent
neuronal diﬀerentiation (Zeng and Zhou, 2008). Smith
et al. (2014) proposed that inhibition of the autophagy
pathway contributes to BDNF-mediated neuronal survival.
Hernandez et al. (2012) showed that autophagy-deﬁcient
mice exhibited enhanced presynaptic neurotransmission
that was rescued by rapamycin administration. The role
of autophagy was also reported at postsynaptic sites.
Autophagy-mediated a-amino-3-hydroxy-5-methyl-4-iso
xazolepropionic acid (AMPA) receptor degradation
occurred as a result of chemical LTD (Shehata et al.,
2012), and Tang et al. (2014) further demonstrated its role
in dendritic spine pruning.
mTORC1 also controls protein degradation by the
ubiquitin–proteasome system. Fumagalli et al. (2015)
showed that rapamycin treatment in oligodendrocyte pre-
cursor cells enhanced the interaction between E3-
ubiquitin ligase murine double minute 2 (Mdm2) and G-
protein-coupled receptor kinase 2 (GRK2) and the subse-
quent degradation of GRK2. Lower levels of GRK2 delay
the desensitization of G protein-coupled receptor 17
(GPR17), which disturbs oligodendrocyte production and
axonal myelination. Indeed, mTORC1 controls both pro-
cesses in vivo (Bercury et al., 2014; Wahl et al., 2014).
In addition to mTORC1, research over the last few years
clearly shows that mTORC2 also regulates proteasome-
driven protein degradation by acting on E3-ubiquitine
ligase FBXW7 (Koo et al., 2015; Li et al., 2016). Still
unknown, however, is the way in which this mTORC2-
driven regulation of proteasome function contributes to
neuronal function and dysfunction.
mTORC1 was recently shown to regulate the
assembly of the proteasome itself. Yun et al. (2016)
showed that the increased activity of mTORC1 promotes
the assembly of immunoproteasomes. Immunoprotea-
somes diﬀer in their subunit composition from constitutive
ones and are assembled in cells in response to oxidative
stress and proinﬂammatory cytokines (Johnston-Carey
et al., 2015). The mechanism by which mTORC1 regu-
lates proteasome formation appears to be mediated by
PRAS40, which interacts with immunoproteasome sub-
units. These authors speculated that this response can
occur in cells that present hyperactive mTORC1, in which
increased protein synthesis can lead to the increased for-
mation of misfolded, oxidized, or aggregated proteins that
require clearance. Recent studies suggest that immuno-
proteasomes are activated in epilepsy (Mishto et al.,
2011, 2015).
Transcription and RNA processing. Another cellular
function of mTORC1 that is receiving more attention is
the regulation of transcription and RNA processing.
mTOR modulates the transcription of genes that are
transcribed by all three RNA polymerases (Pol I, Pol II
and Pol III). The growth factor- and rapamycin-
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sequences that are used by all three RNA polymerases
has been reported (Mayer et al., 2004; Mayer and
Grummt, 2006; Tsang et al., 2010), but the eﬀects of
mTOR on transcription have mostly been studied at the
level of regulating the accessibility or activity of other tran-
scription factors (e.g., Maf1, sterol regulatory element-
binding protein 1 [SREBP1], transcription factor EB
[TFEB], and hypoxia-inducible factor 1-a [Hif1a]; Hudson
et al., 2002; Porstmann et al., 2008; Shor et al., 2010;
Pen˜a-Llopis et al., 2011; Fig. 3C). Additionally, recent dis-
coveries suggest the involvement of mTOR in the post-
transcriptional processing of diﬀerent classes of RNA
(Ye et al., 2015).
The involvement of mTOR in transcription has been
discussed extensively elsewhere (Malik et al., 2013b).
Below we focus speciﬁcally on issues that are related to
neurons. Under basal conditions, acute rapamycin treat-
ment does not robustly aﬀect mRNA levels in cultured hip-
pocampal slices (Blazejczyk et al., 2016). The stimulation
of these neuronal preparations with kainic acid (KA; an
agonist of kainate-type ionotropic glutamate receptors)
revealed some eﬀects of mTOR inhibition on gene
expression. For example, we identiﬁed a small set of
genes, the KA-induced expression of which was substan-
tially diminished by mTORC1 inhibition. The overexpres-
sion of one of these genes, engulfment and cell motility
1, in cultured hippocampal neurons was suﬃcient to
increase the axonal branching pattern and change den-
dritic spine morphology to be more like less mature neu-
rons (Blazejczyk et al., 2016). However, in our work, we
did not identify any particular transcription factor that is
needed for KA-mTOR-driven gene expression. Some
transcription factors that were mentioned above (e.g.,
Hif1a) are important for nervous system development
and neuronal plasticity. An increase in Hif1a levels pro-
motes the dendritic arbor complexity of neurons that are
postnatally born in the subventricular zone (SVZ; Zhang
et al., 2016). Hif1a knockdown prevents ectopic dendrite
formation that is induced by Tsc1 knockout (KO), sug-
gesting that Hif1a acts downstream of Tsc-mTORC1
(Feliciano et al., 2013). Unknown are the Hif1a-
regulated transcripts that are needed for mTOR-driven
dendritic growth. Malik et al. (2013a) screened potential
modiﬁers of dendritic arbor growth, the transcription of
which depends on mTORC1. CCN1/Cyr61 was among
the positive hits. CCN1 is a matricellular protein (Malik
et al., 2013a, 2015), the transcription of which is regulated
by HIF1a in non-neuronal cells (Meyuhas et al., 2008).
Whether Hif1a is responsible for mTORC1-dependent
CCN1 transcription during dendritogenesis remains to
be established, but CCN1 overexpression, similar to Hif1a
overexpression, was suﬃcient to induce dendritic growth
(Malik et al., 2013a). Other processes that are regulated
by Hif1a in neurons include the formation of dendritic
spines and synaptic transmission (Huang et al., 2010,
2012).Cytoskeleton. Another aspect of mTOR activity that is
being investigated in the context of proper neuronal
development and physiology is control of thecytoskeleton (Fig. 3D). mTORC2 has received the most
attention because it is an important modulator of the
actin network (Jacinto et al., 2004; Huang et al., 2013).
The way in which mTORC2 regulates actin dynamics is
still debated, and new mechanisms are constantly emerg-
ing (Angliker and Ru¨egg, 2013; Li and Gao, 2014;
Chantaravisoot et al., 2015). In neurons, two potential,
although not mutually exclusive, mechanisms have been
described. The Ruegg group showed that neuron-
speciﬁc Rictor knockout (Rictorﬂ/ﬂ;Nestin-Cre) substan-
tially reduces the phosphorylation of several isoforms of
protein kinase C (PKC) and its targets that are potentially
involved in the control of actin dynamics (e.g., myristoy-
lated alanine-rich C-kinase substrate [MARCKS],
growth-associated protein 43 [GAP-43], and adducins;
Angliker and Ru¨egg, 2013; Thomanetz et al., 2013). In
contrast, Huang et al. (2013) suggested that mTORC2
controls actin dynamics by interacting with T-cell lym-
phoma invasion and metastasis 1 (Tiam1; a Rac1 gua-
nine nucleotide exchange factor) and subsequently
activating the Rac1-Pak1-coﬁlin pathway. Compared with
mTORC2, mTORC1 has been poorly studied in the con-
text of the cytoskeleton, both in non-neuronal cells and
in neurons. An initial observation by Choi et al. (2002)
demonstrated the rapamycin-dependent phosphorylation
of cytoplasmic linker protein of 170 kDa (CLIP-170; a
plus-end microtubule-tracking protein). These authors
also showed that rapamycin adversely aﬀected the plus-
end tracking behavior of CLIP-170. Indeed, our study con-
ﬁrmed that CLIP-170 is phosphorylated by mTOR, but we
did not observe the detachment of CLIP-170 from micro-
tubule plus ends upon rapamycin treatment. Instead,
mTOR regulated CLIP-170 binding with IQ motif-
containing GTPase-activating protein 1 (IQGAP1) and
F-actin, which supported the formation of new dendritic
branches (Swiech et al., 2011).Additional functions of mTORCs. mTORC2 also
plays a role in regulating cellular metabolism by
controlling the activity of several downstream kinases.
Among these, Akt, SGK1, and PKCa are the best
studied to date, and all three play roles in neuronal
morphology (see below). mTORC2 also regulates the
integrity of mitochondrion-associated membranes
(MAMs), which facilitate the transfer of calcium and
lipids between the ER and mitochondria. Betz et al.
(2013) showed that mTORC2 is translocated to the
MAM upon insulin stimulation, and MAM-associated
mTORC2 can phosphorylate Akt and maintain the
structure and stability of MAMs. Mitochondrion-
associated membranes are critical for neuronal survival,
and their dysfunction appears to contribute to neurode-
generation (Hedskog et al., 2013; Guardia-Laguarta
et al., 2015).CONTRIBUTION OF mTOR TO NERVOUS
SYSTEM DEVELOPMENT AND PHYSIOLOGY
mTOR is critical for proper neuronal development (e.g.,
during axonogenesis and axon guidance [Piper et al.,
2006, 2015; Morita and Sobue, 2009; Nie et al., 2010],
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2005; Urbanska et al., 2012; Skalecka et al., 2016],
and the genesis of dendritic spines [Kumar et al.,
2005] and neuronal physiology [e.g., learning, memory,
and synaptic plasticity; for review, see Jaworski and
Sheng, 2006; Swiech et al., 2008]). The involvement of
mTOR has been demonstrated for diﬀerent types of neu-
rons, diﬀerent parts of the nervous system, almost all
kinds of neuronal plasticity (e.g., LTP, LTD, and chemi-
cal LTD), and diﬀerent learning and memory processes
(Jaworski and Sheng, 2006; Garelick and Kennedy,
2011; Bockaert and Marin, 2015). mTOR is also impor-
tant for feeding and body weight control (Yang et al.,
2012; Vinnikov et al., 2014), circadian rhythm (Cao
et al., 2013), and nociception (Khoutorsky et al., 2015).
mTOR activity also contributes to nervous system regen-
eration (Berry et al., 2016). Several of these ﬁndings are
discussed above and reviewed elsewhere (Jaworski and
Sheng, 2006; Swiech et al., 2008; Garelick and
Kennedy, 2011; Lipton and Sahin, 2014; Bockaert and
Marin, 2015). Important progress is still being made.
Interesting developments in this area include the follow-
ing: (i) ﬁnal proof of the importance of mTOR in neurode-
velopment in vivo and detailed studies of the role of
mTORC1 in early steps of neurogenesis, (ii) a better
understanding of the role of mTORC2 in the central ner-
vous system, and (iii) the identiﬁcation of novel functions
of mTORC1 in the central nervous system beyond the
control of protein synthesis. The last of these issues is
discussed above. The following sections speciﬁcally
focus on the ﬁrst two.
Role of mTORC1 in neurodevelopment in vivo
Establishing proper brain morphology requires the proper
temporal and spatial organization of neuron birth,
migration, and diﬀerentiation. The standardization and
widespread availability of in vivo electroporation
protocols and development of conditional transgenic
animal models that directly aﬀect mTORC1 activity
revealed that many of these processes in vivo are
controlled by the mTORC1 pathway. This is an
important step forward because most of our knowledge
of the potential functions of mTORC1 in neuronal
development was obtained using Tsc1, Tsc2, Pten, and
Nf1 KO mice, which serve as models of aberrant
hyperactivation of mTOR in disease states (Table A.1).
Although the knowledge that is gained by studying these
models is greatly important, all of these proteins have
eﬀectors other than the mTORC1 signaling pathway
(Trovo´-Marqui and Tajara, 2006; Neuman and Henske,
2011; Alves et al., 2015).
Several recent studies concentrated on the role of
mTORC1 during early steps of neurogenesis, both
embryonic and postnatal. Although some diﬀerences
appear to exist between these two phenomena,
research suggests that tightly controlled mTORC1
activity is needed for neural stem cell (NSC)
proliferation, survival, and diﬀerentiation. Cloetta et al.
(2013) crossed Rptorﬂ/ﬂ mice with mice that expressed
CRE recombinase under the Nestin promoter (Rptorﬂ/ﬂ;
Nestin-Cre), which allowed the removal of Rptor speciﬁ-cally in NSCs and their progeny. The resultant conditional
knockout (cKO) mice, although born in a Mendelian ratio,
had microcephaly and were dying just after birth. Detailed
analyses revealed fewer neurons in the brain in Rptorﬂ/ﬂ;
Nestin-Cre mice. The decrease in the number of neurons
resulted from a combination of lower neurogenesis and an
increase in apoptotic cell death of already diﬀerentiated
Tuj1-positive neurons. With regard to neurogenesis, the
cell cycle of Rptorﬂ/ﬂ;Nestin-Cre ventricular zone (VZ)
NSCs was extended, aﬀecting their rate of proliferation.
Intriguingly, mice that also expressed a hyperactive
mutant of mTOR early prenatally only in Emx1-
expressing NSCs in the developing cortex had smaller
brains because of cortical atrophy (Kassai et al., 2014).
In this case, however, atrophy was attributable to the pro-
nounced death of T-box brain protein 2 (Trb2)-positive
neuronal progenitors in the embryonic SVZ. An expres-
sion analysis of Hif1a and its target, cyclin-dependent
kinase inhibitor 1A, led the authors to conclude that cell
death was mediated by Hif1a. The eﬀect of mTOR hyper-
activity on NSC survival can be age-dependent. Using the
same active mutant of mTOR, Kassai et al. (2014)
showed that the late initiation of transgene expression
on postnatal day 2 (P2) did not have such a dramatic
impact on cell survival. At this developmental stage, the
electroporation of Hif1a to NSCs in the SVZ did not cause
major neurotoxicity. Instead, the knockdown of Hif1a or its
inhibition by echinomycin had deleterious eﬀects on neu-
ronal survival (Feliciano et al., 2013).
mTORC1 inhibition was shown to have adverse
eﬀects on the number of neurons that were born
postnatally in the SVZ (Hartman et al., 2013). In this case,
however, no eﬀects of either Raptor or Rheb knockdown
on the proliferation or survival rate of NSCs were
reported. Instead, the inhibition of mTORC1 activity
decreased the diﬀerentiation of NSCs toward transit
amplifying cells (TACs), which give rise to neuroblasts
that migrate toward the olfactory bulb. In the same model,
mTOR hyperactivation led to the depletion of NSCs
through accelerated diﬀerentiation to TACs. mTORC1-
dependent protein translation that is regulated by 4E-
BPs was also found to be responsible for the diﬀerentia-
tion of NSCs (Hartman et al., 2013). At the same time,
p70S6K was not involved in diﬀerentiation but rather con-
trolled the size of the cell soma. Additional work on pho-
toreceptor diﬀerentiation timing in Drosophila suggested
that additional factors downstream of mTOR, such as
RNA-binding protein Unkempt (Unk), may also be
involved (Avet-Rochex et al., 2014). In contrast, GSK3
was identiﬁed as an upstream regulator of the mTOR
pathway during the maintenance and self-renewal of neu-
ral progenitors. The inactivation of mTORC1 by rapamy-
cin suppressed the abnormal proliferation of neural
progenitors that was induced by GSK3 deletion (Ka
et al., 2014). mTOR also positively regulates the genera-
tion of astrocytes and diﬀerentiation of oligodendrocytes
(Bercury et al., 2014; Wahl et al., 2014).
Several examples suggest that mTORC1 is also
involved in the control of late neurogenesis, which
follows neuron birth and initial lineage speciﬁcation.
Kassai et al. (2014) electroporated hyperactive mTOR in
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tion from the VZ to the pial surface in the intermediate
zone of the forming cerebral cortex. The break in migra-
tion was released by either rapamycin treatment or the
co-electroporation of shRNAs that targeted Raptor or
S6K1 mRNA. The aberrant migration of neurons through
the hyperactivation of mTOR was not seen solely in the
developing cortex. The Bordey group showed that the
constitutive activation of Rheb in neural progenitor stem
cells of the SVZ increased mTOR activity and led to dis-
ruptions in their neuronal migration to the olfactory bulb
and abnormal neuron morphology and circuit formation
(Lafourcade et al., 2013). These results are consistent
with migration phenotypes that were described previously
in Tsc1 KO mice, suggesting that hyperactive mTORC1
might be a major contributor to defects in migration that
are observed in TSC patients. Nonetheless, much less
is known about the inﬂuence of lower mTORC1 activity
on neuronal migration. Our recent study did not directly
focus on migration analysis per se, but it showed that neu-
roblasts in mTORﬂ/ﬂ mice that were electroporated with a
plasmid that constitutively expressed CRE migrated from
the SVZ through the rostral migratory stream (RMS) to the
olfactory bulb and diﬀerentiated into neurons (Skalecka
et al., 2016).
mTOR is known to control axon and dendrite
development in neurons that are cultured in vitro and in
organotypic slice preparations (Swiech et al., 2008).
Gong et al. (2015) recently showed that the activation of
mTORC1 in vivo by means of the in utero electroporation
of E15 mice with a plasmid that encoded constitutively
active Rheb substantially increased axon growth in layer
2/3 cortical neurons. This eﬀect was mediated by the
mTORC1 canonical eﬀectors 4E-BP1/2 and S6K1/2.
However, S6Ks were suggested to regulate microtubules
by inhibiting the IRS1-PI3K-Akt pathway and subse-
quently activating GSK3 rather than by controlling protein
synthesis (Gong et al., 2015). mTORC1 also has an
impact on proper axon myelination in both the central
and peripheral nervous systems (Bercury et al., 2014;
Lebrun-Julien et al., 2014; Norrme´n et al., 2014). More
detailed studies of the peripheral nervous system showed
that this process requires the Raptor-dependent regula-
tion of sterol synthesis in Schwann cells (Norrme´n et al.,
2014). Several studies in Tsc1, Tsc2, and Pten KO mice
suggested that increased mTOR activation leads to
excessive and improper dendritic arborization
(Table A.1). However, the requirement of mTOR for phys-
iologically occurring dendritic arborization in vivo was pro-
ven only recently. Using neonatalmTORﬂ/ﬂmice that were
electroporated with CRE, Skalecka et al. (2016) showed
that the removal of mTOR from NSCs in the SVZ on
P0-P1 profoundly simpliﬁed both apical and basal den-
dritic arbors of descendant neurons, which reached and
diﬀerentiated in the olfactory bulb.Role of mTORC2 in the nervous system
Much less is known about the function of mTORC2 in the
nervous system. This is likely because rapamycin is used
as a tool to study mTOR in neurons. The ﬁrst report of therole of mTORC2 in neurons came from a study of
dendritogenesis in Drosophila. In class IV dendrite
arborization (da) sensory neurons, TORC2, together
with tricornered kinase, was shown to control dendritic
tiling. During this process, dendrites of the same
neuronal class actively avoided crossing each other and
formed non-overlapping dendritic ﬁelds (Koike-Kumagai
et al., 2009). Soon afterward, the importance of mTORC2
in dendritogenesis was also described in cultured mam-
malian hippocampal neurons in vitro (Urbanska et al.,
2012; Thomanetz et al., 2013). Urbanska et al. (2012)
showed that Rictor knockdown led to the simpliﬁcation
of dendritic tree morphology through the inhibition of
new dendritic branch formation. The lack of Rictor also
aﬀected the BDNF-induced dendritic branching of
SVZ-derived neurons that were cultured in vitro
(Skalecka et al., 2016). At least two mechanisms by which
mTORC2 controls dendritogenesis have been proposed.
Results from the Ruegg laboratory show that the
mTORC2-dependent control of actin dynamics is needed
for normal dendritic growth (Angliker and Ru¨egg, 2013;
Thomanetz et al., 2013). Our team identiﬁed Akt-
mTORC1 as a downstream eﬀector of mTORC2, which
controls dendritic growth. Rictor knockdown decreased
Akt phosphorylation and simpliﬁed dendritic trees, which
could be rescued by Akt or S6K1 overexpression
(Urbanska et al., 2012).
Mouse models that lack Rictor expression in speciﬁc
areas of the brain have been generated only recently,
accelerating studies of the role of mTORC2 in the
nervous system in mammals in vivo. Carson et al.
(2013) reported reductions of brain size in mice with Rictor
KO selectively in the dorsal cortex (Rictorﬂ/ﬂ;Emx1-Cre).
However, this decrease was proportional to an overall
reduction of body size. A non-proportional decrease was
achieved by conditionally deleting Rictor in the entire
central nervous system by crossing Rictorﬂ/ﬂ mice with
Nestin-Cre mice. These mice had a 40% reduction of
brain size at birth (Thomanetz et al., 2013). The reduction
was uniform throughout all of the analyzed brain areas
(i.e., cortex, hippocampus, striatum, and olfactory bulb).
More detailed analyses of hippocampal CA1 pyramidal
and cerebellar Purkinje neurons revealed that the
observed microcephaly was not an eﬀect of a decrease
in proliferation or dramatic increase in cell death but rather
stemmed from a reduction of neuronal cell soma size and
fewer dendritic arbors. An additional observation in
Purkinje cells was that these neurons, which normally
develop single apical primary dendrites, grew multiple
dendrites in the absence of Rictor (Thomanetz et al.,
2013). Electrophysiology revealed that the lack of Rictor
also resulted in a decrease in both excitatory and inhibi-
tory basal synaptic transmission (Thomanetz et al.,
2013). These changes in the cerebellum led to clear
deﬁcits in motor skills in Rictor KOmice in the rotarod test.
The use of Purkinje neuron-speciﬁc Rictor KO (Rictorﬂ/ﬂ;
L7/Pcp-2-Cre) allowed deciphering the deﬁcits that are
intrinsic to Rictor’s actions in Purkinje cells and the deﬁcits
that stem from whole-cerebellar network dysfunction.
Such KO produced morphological defects but not
synaptic defects (Thomanetz et al., 2013).
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transmission were performed using conditional,
postnatal forebrain-speciﬁc Rictor KO (Rictorﬂ/ﬂ;
CaMKIIa-Cre) mice (Huang et al., 2013). Such Rictor
KO resulted in the inhibition of L-LTP but not early LTP
(E-LTP) in hippocampal slices. These authors also
showed that Rictorﬂ/ﬂ;CaMKIIa-Cre mice formed signiﬁ-
cantly fewer dendritic spines and suﬀered from deﬁcits
in the formation of both contextual and cued long-term
memory (Huang et al., 2013). These deﬁcits were
likely attributable to disturbances in actin dynamics,
and F-actin-stabilizing drugs rescued both the
electrophysiological and cognitive deﬁcits. Furthermore,
these authors showed that A-443654, a drug that induces
mTORC2 activity, enhanced both L-LTP and long-term
memory in wildtype mice (Huang et al., 2013). This obser-
vation may have further practical implications in the con-
text of a recent report that demonstrated that mTORC2
activity and long-term memory both decrease with age,
and A-443654 restored performance in aged mice to the
level of young mice (Johnson et al., 2015).
In addition to classic learning and memory paradigms,
Rictor KO mice were tested in a wide variety of behavioral
tests. One of the ﬁrst ﬁndings regarding the function of
mTORC2 in the mammalian brain was that mice with
neuron-speciﬁc conditional Rictor KO (Rictorﬂ:ﬂ;Nestin-
Cre) exhibited lower levels of Akt phosphorylation,
leading to the disruption of dopaminergic signaling and
neurochemical and behavioral phenotypes associated
with schizophrenia and anxiety (Siuta et al., 2010). Pre-
pulse inhibition was disrupted in Rictor KO mice. In
Emx1-Cre-induced Rictor KO mice, Carson et al. (2013)
reported that the lack of Rictor in only one part of the cor-
tex increased locomotor activity and novelty-induced
insomnia and decreased anxiety-like behavior. Addition-
ally, the contribution of mTORC2 to reward-seeking
behavior was demonstrated using local Rictor KO and
local active Rictor (T1135A) overexpression in ventral
tegmental area neurons. Using these experimental mod-
els, Mazei-Robison et al. (2011) showed that Rictor KO
decreased morphine-induced conditioned place prefer-
ence, and Rictor (T1135A) overexpression led to the
opposite response.mTOR-RELATED DISEASES OF THE NERVOUS
SYSTEM
Genetic diseases
Mutations in the genes that encode components of the
mTOR signaling pathway result in genetic diseases with
severe neurological symptoms. Although these genetic
syndromes have their own unique features, they also
have several similarities, including epilepsy, benign
tumor formation, autism, and intellectual disability. Data
from existing animal models (Table A.1) strongly
support a causal link between mTOR dysregulation and
these clinical manifestations. Below we discuss a few
genetic disorders for which the involvement of mTOR
has been the most intensively investigated.Tuberous sclerosis complex. Tuberous sclerosis
complex is a multi-system autosomal dominant disorder
and the best studied mTORopathy to date. Primary
manifestations of TSC are benign tumors and lesions in
various organs of the body, with cortical tubers,
subependymal nodules (SENs), subependymal giant cell
astrocytomas (SEGAs), retinal hamartomas, and
cerebral white matter migration tracts in the nervous
system. Recent progress in brain imaging revealed
additional manifestations of TSC in the nervous system,
including cerebellar tubers (Ertan et al., 2010), hypomyeli-
nation in some brain areas (e.g., the frontal lobe, pons,
and corpus callosum; Arulrajah et al., 2009; Simao
et al., 2010), and a tendency toward a decrease in the
diameter of the optic nerve (Gialloreti et al., 2015). The
most common clinical neurological symptoms of TSC
include epilepsy (in 80–90% of aﬀected individuals), intel-
lectual disability (60%), and autism spectrum disorder
(ASD; 25–50%; Crino et al., 2006; Curatolo et al., 2008,
2015). Some patients also suﬀer from other neuropsychi-
atric disorders, including anxiety, depression, attention-d
eﬁcit/hyperactivity disorder (ADHD), and aggressive/dis-
ruptive behavior (Muzykewicz et al., 2007).
The majority (80–85%) of TSC cases diagnosed to
date are caused by mutations in either the TSC1 or
TSC2 gene (Fig. 4). A large number of mutations have
been reported for both TSC genes (>200 for TSC1 and
>700 for TSC2; Dabora et al., 2001; Sancak et al.,
2005). Other unknown TSC genes have also been sug-
gested. Mutations in TCB1D7 were recently reported,
but the clinical presentation in these patients appeared
to be diﬀerent from TSC (Capo-Chichi et al., 2013;
Alfaiz et al., 2014). Moreover, in the majority of patients
in whom standard gene sequencing identiﬁes no muta-
tion, more comprehensive studies can detect mosaic or
intronic mutations in either the TSC1 or TSC2 gene, indi-
cating that the existence of other TSC genes is less likely
(Tyburczy et al., 2015). Establishing a genotype–pheno-
type association in TSC has been diﬃcult because of
the large number of mutations and mosaicism. To date,
most studies suggest that TSC symptoms are generally
more severe in patients with TSC2 mutations than in
patients with TSC1 mutations (Dabora et al., 2001;
Curatolo et al., 2015).
To better understand the mechanisms of disease
progression and study cellular and molecular defects in
TSC, several animal models have been established
(Table A.1), including rats (Ecker rats), mice, zebraﬁsh,
and Drosophila. The complete deletion of either Tsc1 or
Tsc2 results in embryonic death in mice. Thus, studies
are mostly performed in heterozygous or cKO animals
with Tsc genes that are selectively inactivated in a
chosen cell type or brain region. Using this strategy,
mice have been developed that lack either Tsc1 or Tsc2
in NSCs, neuroblasts, diﬀerent subtypes of developing
or adult neurons (e.g., excitatory or inhibitory),
astrocytes, and oligodendrocytes (Table A.1). Mouse
models are also available in which Tsc gene KO can be
induced by either doxycycline or tamoxifen. To date,
however, no single transgenic or KO mouse can fully
recapitulate the complicated phenotype of TSC in
Fig. 4. Cell signaling dysfunction in genetic diseases with changed mTOR activity caused by
mutations in TSC1, TSC2, PTEN, AKT, NF1 and FXR1. See text for more details.
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phenotypes that are found in ‘‘TSC mice.” Generally,
heterozygous mice survive normally, do not display
typical anatomical changes that are observed in
patients’ brains (e.g., tubers, SENs, SEGAs, and white
matter changes), and are mostly used in studies that
evaluate behavioral dysfunction in TSC (Table A.1). A
lack of spontaneous seizures was considered one
disadvantage of using Tsc1+/ and Tsc2+/ mice as
models of TSC. Recently, however, early postnatal
intracortical electroencephalography (EEG) in Tsc1+/
mice revealed transient seizures between P9 and P18 in
approximately 80% of the animals (Lozovaya et al.,
2014). Mice with early gene deletion that is restricted to
selected cell populations (e.g., NSCs and developing neu-
rons) are generally excluded from behavioral studies
because of their poor survival. Instead, such animal mod-
els are mostly exploited to study cellular and anatomical
abnormalities (e.g., the appearance of enlarged neurons,
balloon-like vacuolized cells, and cells that simultane-
ously express neuronal and glial markers) and seizure
progression. Only a few studies reproduced more com-
plex abnormalities that resemble cortical tubers, SENs,
and SEGAs (Table A.1). Some phenotypes (e.g., those
that exhibit a decrease in the caliber of the optic nerve)
have not yet been reported in mammalian models but
are observed in zebraﬁsh (Fig. 5).
Clinical observations, extensive studies of animal
models of TSC, and biochemical analyses of the
TSC1–TSC2 protein complex undoubtedly point to
mTORC1 hyperactivity as a molecular cause of TSC.
Nevertheless, recent studies suggest additional
contributions of decreases in mTORC2 activity, non-
mTORC1-related eﬀectors of TSC, and individualcellular functions of TSC1 and
TSC2 to TSC (Switon et al., 2016).
Increases in mTORC1 activity are
repeatedly reported in pathologically
altered cells that are found within
tubers, SENs, and SEGAs in TSC
patients (Baybis et al., 2004; Chan
et al., 2004). The potential contribu-
tion of mTORC1 to TSC pathology
is further corroborated by observa-
tions that several pathogenic muta-
tions in Tsc1 or Tsc2 lead to an
increase in mTORC1 activity in
cultured cells (Hoogeveen-
Westerveld et al., 2012, 2013). How-
ever, causal relationships between
particular TSC symptoms in humans
and mTORC1 activity are not always
unequivocally proven. The inhibition
of mTORC1 with rapalogs prevents
SEGA growth (Kotulska et al.,
2013; Krueger et al., 2013; Franz
et al., 2015). Some examples also
exist for the inhibitory eﬀects of rapa-
logs on epilepsy progression and the
rapamycin-induced reduction of ASD
and speciﬁc neurocognitive symp-
toms (Kotulska et al., 2013; Franzet al., 2015; Hwang et al., 2016). Most of our knowledge
concerning the direct role of mTORC1 in TSC comes
from animal models. Some studies reported that stron-
ger mTORC1 activation is correlated with more severe
phenotypes. For example, Zeng et al. (2011) observed
higher phosphorylation of rpS6 protein, earlier death,
and more severe seizures in Tsc2ﬂ/ﬂ;GFAP-Cre KO
mice than in Tsc1ﬂ/ﬂ;GFAP-Cre KO mice. Kwiatkowski
and coworkers who investigated the eﬀect of Tsc2
dosage on TSC outcome, generated mice with diﬀerent
amounts of remaining tuberin (20% and 35% of physio-
logical Tsc2 levels). Using these mice, Yuan et al.
(2012) showed that this 15% diﬀerence in tuberin levels
was suﬃcient to lower mTORC1 activation and improve
the outcome of ‘‘mouse TSC” with regard to both neu-
roanatomical and behavioral abnormalities. Nonethe-
less, the strongest evidence of the involvement of
mTOR in TSC pathology comes from studies that used
rapamycin or its derivatives. As listed in Table A.1,
rapamycin treatment in many TSC models extends the
life span, reduces seizures, decreases the number of
cytomegalic cells, rescues lamination defects, prevents
astrogliosis, improves myelination, and reverses behav-
ioral deﬁcits. However, some aspects of TSC pathology
appear to be independent of mTORC1. For example,
Magri et al. (2011) showed that rapamycin was ineﬀec-
tive in preventing the apoptotic cell death of Tsc1/
neurons that diﬀerentiated in vitro. The self-renewal of
Tsc1+/ embryonic NSCs appeared to occur indepen-
dently from mTORC1 hyperactivation. Alves et al.
(2015) showed that Pak2 acts downstream of the TSC
complex and is responsible for migration deﬁcits, at
least in ﬁbroblasts.
Fig. 5. Optic nerve diameter changes in zebraﬁsh model of TSC.
Representative images of developing zebraﬁsh (genotypes as indi-
cated; Tsc2vu242 – functional KO of Tsc2; (Kim et al., 2011)) retina
stained for retinal ganglion cell marker (Zn-8) to visualize optic nerve
and F-actin (left panel). Quantiﬁcation of optic nerve diamiter.
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drome. Phosphatase and tensin homolog deleted on
chromosome ten (PTEN) hamartoma tumor syndrome
(PHTS) is a spectrum of disorders that is characterized
by loss-of-function mutations in the PTEN gene. PTEN
is a phosphatase that negatively regulates the PI3K/
Akt/mTOR pathway by dephosphorylating PIP3 and
preventing Akt stimulation (Song et al., 2012; Fig. 4). It
also acts as a tumor suppressor in cancers of the human
brain, breast, and prostate (Li et al., 1997). Disorders
that are caused by PTEN mutations include Cowden
syndrome, Lhermitte–Duclos disease, Bannayan–Riley–
Ruvalcaba syndrome, and various cancers (Endersby
and Baker, 2008; Pilarski et al., 2013). Until very
recently, Proteus syndrome was believed to be caused
by a PTEN mutation. Subsequent studies showed that
an underlying cause in many patients with Proteus syn-
drome is a mutation in Akt1, which encodes a protein
that is inhibited by PTEN (Lindhurst et al., 2011). PTEN
mutation disorders, as well as Proteus syndrome, have
overlapping characteristics. Because the same muta-
tions in the PTEN gene can cause any of these syn-
dromes, they may in fact be one disorder (Zori et al.,
1998; Marsh et al., 1999). Secondary factors and
mutations may also play a role in establishing speciﬁcphenotypes (Pilarski et al., 2013). The vast majority of
patients with diﬀerent disorders that are associated with
PTEN mutations exhibits macrocephaly and a higher risk
of benign or malignant tumors. Cowden disease is a rare
disease that is characterized by macrocephaly, a higher
risk of malignant cancers of the breast, thyroid gland,
and endometrium, and benign hamartomas in various
organs of the body (Liaw et al., 1997). Lhermitte–Duclos
disease is characterized by benign neuronal overgrowth
in the cerebellum, which results in an increase in
intracranial pressure, ataxia, and seizures. Dysplastic
neurons express only the mutant allele of PTEN or they
have no PTEN expression at all, which results in ele-
vated Akt levels (Zhou et al., 2003). Bannayan–Riley–
Ruvalcaba syndrome is a disorder with primary clinical
features that include macrocephaly, developmental
delay, hemangiomas, spotted pigmentation of the skin,
scoliosis, and hamartomatous intestinal polyps (Lynch
et al., 2009). PTEN mutations that do not fully abrogate
its phosphatase activity are also found in patients with
ASD (Rodriguez-Viciana et al., 1997; Varga et al.,
2009). However, PTEN mutations were described in only
1% of human ASD patients.
Several mouse models of Pten deﬁciency have been
developed using conditional Pten KO in diﬀerent
neuronal populations or the viral delivery of short-hairpin
RNAs (shRNAs) against Pten mRNA (Table A.1). These
mice exhibit numerous abnormalities at the cellular,
anatomical, physiological, and behavioral levels.
Changes in mTOR pathway activity have also been
repeatedly reported (Kwon et al., 2003, 2006; Amiri
et al., 2012; Pun et al., 2012; Sperow et al., 2012; Zhu
et al., 2012; Lugo et al., 2013; Chen et al., 2015;
Nguyen et al., 2015). Nonetheless, the causal role of
mTOR in Pten KO phenotypes has been studied in only
a few cases. The ﬁrst described mouse model that lacked
Pten was Ptenﬂ/ﬂ;GFAP-Cre (also known as NS-Pten
KO). In this model, Pten was deleted in several NeuN-
positive cells (Backman et al., 2001; Kwon et al., 2001;
Nguyen et al., 2015). These mice were characterized by
a shortened lifespan, severe epilepsy, and neuronal
hypertrophy in the hippocampus and cerebellum. Chronic
rapalog (CCI-779) treatment decreased death and sei-
zure frequency in these mice. The average diameter of
neurons also decreased, although the eﬀects on cerebel-
lar neurons required higher doses of CCI-779 (Kwon
et al., 2003). Ljungberg et al. (2009) showed that even rel-
atively short rapamycin treatment for 2 weeks vs. 6 weeks
(Kwon et al., 2003) prior to seizure development was suf-
ﬁcient to prevent activation of the mTOR pathway, cortical
neuron hypertrophy, and the development of severe epi-
lepsy. Importantly, the antiepileptogenic eﬀect lasted for
3 weeks after rapamycin discontinuation. Sunnen et al.
(2011) subsequently found that even a single dose of
rapamycin that was administered in NS-Pten KO mice
early during the epileptogenic process (4 weeks of
age) blocked seizure recurrence and aberrant mossy ﬁber
sprouting for a few weeks. Additional doses of rapamycin
at later time points (11 and 16 weeks) delayed Pten KO-
related pathology even further. Finally, the ability of rapa-
mycin to inhibit seizures and increase the rate of survival
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recently reported (Nguyen et al., 2015). Rapamycin also
eﬃciently reversed astrogliosis and microgliosis
(Nguyen et al., 2015). In other models, rapalogs also
eﬀectively prevented neuropathology that was related to
a lack of Pten. For example, in Ptenﬂ/ﬂ;Nex-Cre KO mice
that lack Pten selectively in excitatory neurons of the fore-
brain, rapamycin administration at birth substantially
increased the rate of survival (Kazdoba et al., 2012).
Interesting insights into the role of mTOR in Pten
KO-related pathology have come from studies that used
animals in which Pten was selectively removed from
postnatally born neurons in the dentate gyrus of the hip-
pocampus and SVZ (Ptenﬂ/ﬂ;Nestin-Cre-ERT2 and
Ptenﬂ/ﬂ;Gli-Cre-ERT2, respectively; (Pun et al., 2012;
Zhu et al., 2012). In Ptenﬂ/ﬂ;Nestin-Cre-ERT2 mice, gene
KO was induced on P30, resulting in the premature diﬀer-
entiation of neuroblasts and subsequent SVZ expansion.
This eﬀect was prevented by rapamycin, underscoring the
importance of mTORC1 silencing during the physiological
migration of neurons. Pun et al. (2012) speciﬁcally
removed Pten in adult-born granule cells of the dentate
gyrus, resulting in rapamycin-sensitive, progressive epi-
lepsy and the aberrant sprouting of mossy ﬁber axons.
Although the ﬁndings discussed above reveal the
contribution of mTOR to PTEN-related syndromes,
recent work by Chen et al. (2015) suggests that this might
be the case only when selective mutation leads to a
>50% decrease in Pten activity. Supporting this hypoth-
esis, the authors found that heterozygous Pten KO mice
(Pten+/ or Ptenﬂ/+;Emx1-Cre) did not exhibit increases
in mTORC1 activity, although cortical hypertrophy was
evident. This hypertrophy stemmed from b-catenin
pathway-induced hyperplasia, and neither mTOR nor
Rptor KO was able to reverse it. However, when a second
copy of Pten was removed (Ptenﬂ/ﬂ;Emx1-Cre), the mice
displayed more substantial hypertrophy of the cortex. This
augmented increase in cortex size coincided with
mTORC1 pathway hyperactivation and cellular over-
growth. These results suggest that similar brain pheno-
types (i.e., brain hypertrophy) can occur, depending on
the degree of Pten inactivation, but the underlying molec-
ular mechanisms diﬀer. This also raises the question of
whether autistic-like behaviors that are observed in
Pten+/ mice are mTOR-dependent.
Malformations of cortical development. Malformations
of cortical development (MCD) comprise a group of
diseases with diﬀerent origins, the common feature of
which is abnormal development of the cerebral
cortex, either globally or locally. Malformations of
cortical development include megalencephaly,
hemimegalencephaly, and focal cortical dysplasia
(FCD). Megalencephaly is characterized by symmetric
enlargement of the cortex. Hemimegalencephaly aﬀects
only one hemisphere. In FCD, only localized
abnormalities are found throughout the cortex. Focal
cortical dysplasia can be further subdivided into three
types: Type I, Type II, and Type III. Type II is
characterized by changes in cortical architecture and
cellular abnormalities, including dysmorphic neurons.The presence of balloon cells causes further subdivision
of FCDII into a (w/o) and b (with) subclasses. FCDIIb
presents several similarities to pathological changes that
are found in the cortex in TSC patients. Patients with
MCD often suﬀer from intractable epilepsy, which can
be treated with surgery. The similarities between MCD
and TSC prompted researchers to investigate mTOR
pathway activation in brain samples from MCD patients.
Subsequently, increases in mTOR signaling were
repeatedly reported in pathologically altered cells (i.e.,
cytomegalic neurons and balloon cells).
Progress in sequencing and sequencing data analysis
greatly advanced the search for the genetic causes of
MCD. Several studies that involved dozens of patients
revealed that pathogenic mutations in megalencephaly,
hemimegalencephaly, and FCDII often occur only
somatically in a small part of neuronal cells and are
found in genes that encode proteins of the PI3K-Akt-
mTOR pathway or its regulators, including DEPDC5,
PIK3CA, AKT3, LYK5 (STRADA), and mTOR itself
(Table 1). DEPDC5 encodes DEP domain-containing
protein 5, which is a component of the GATOR
complex. Mutations in DEPDC5 lead to mTOR
activation. LYK5 encodes STE20-related kinase adaptor
protein a, which is required for the activity of LKB1
kinase, which in turn inhibits mTORC1 via AMPK.
PIK3CA and AKT3 encode activators of the mTOR
pathway, mutations of which increase their activity.
Finally, the majority of mTOR mutations that have been
identiﬁed in the brain to date are gain-of-function
mutations that increase mTORC1 activity in dysplastic
cells in patient specimens and in vitro cultured cells
(Table 1). These mutations typically map to the FAT or
kinase domains (Fig. 1). Analyses of the available
mTOR structure imply that these mutations increase the
accessibility of the active site for the substrates. Another
possible mechanism of mTOR activation in the case of
some mutations that are found in the FAT domain is
loss of the interaction between mTOR and Deptor, an
inhibitory component of mTORC1.
Altogether, the above ﬁndings suggest that changes in
mTOR signaling underlie MCD. However, this hypothesis
has been diﬃcult to prove. First, although the
aforementioned mutations were not found in control
samples from non-MCD patients, no mutations in these
genes were found in a substantial number of patients
with MCD. Second, although mTOR activity increased in
cells that contained the mutation, it also often increased
in pathologically altered cells that lacked it. Third, until
only recently, no relevant animal models were available.
Nevertheless, some recent ﬁndings may shed light on
the potential link between mTOR and MCD and the use
of mTOR inhibitors as a treatment strategy. Correlations
between the levels of mTOR mutation in samples that
were obtained during parietotemporal lobectomy and
intraoperative electrocorticography revealed that the
highest mutation frequency was in the epicenter of
epilepsy and dropped to zero at the edges of the
resected area (Mirzaa et al., 2016). The authors also cor-
related the level of mTORC1 activation that was caused
by particular mutations with the observed phenotypes.
Table 1. Brain pathology-related mTOR mutations
mTOR mutation Disease phenotype mTOR activity Rapa eﬀects Refs.
Cys1483Tyr HME/CD mTORC1 up Yes Lee et al. (2012), D’Gama et al. (2015), Mirzaa et al. (2016)
Ser2215Tyr FCDIIb; FCDIIa mTORC1 up Yes Nakashima et al. (2015), Mirzaa et al. (2016)
Ser2215Phe FCDIIb; FCDIIa mTORC1 up Yes Lim et al. (2015), Nakashima et al. (2015), Mirzaa et al. (2016)
Ala1459Asp FCDIIb mTORC1 up Not analyzed Nakashima et al. (2015)
Leu1460Pro FCDIIb; FCDIIa mTORC1 up Yes Nakashima et al. (2015), Mirzaa et al. (2016)
A1669S HME Not analyzed Not analyzed D’Gama et al. (2015)
W1456G FCDIIa mTORC1 up Not analyzed Leventer et al. (2015)
Leu2427Pro FCDIIa mTORC1 up Yes Lim et al. (2015)
Arg2193Cys FCDIIa Not analyzed Not analyzed Lim et al. (2015)
Arg624His FCDIIa Not analyzed Not analyzed Lim et al. (2015)
Arg1709His FCDIIa Not analyzed Not analyzed Lim et al. (2015)
Leu2427Gln FCDIIb mTORC1 up Not analyzed Lim et al. (2015)
Thr1977Lys FCDIIb Not analyzed Not analyzed Lim et al. (2015)
Thr1977Ile ME mTORC1 up Yes Mirzaa et al. (2016)
Tyr1450Asp FCDIIb Not analyzed Not analyzed Lim et al. (2015)
Cys1483Arg FCDIIb/ME_HME mTORC1 up Not analyzed Lim et al. (2015)
Glu1799Lys ME mTORC1 up Yes Baynam et al. (2015), Mroske et al. (2015), Mirzaa et al. (2016)
ME – megalencephaly, HME – hemimegalencephaly, FCD – focal cortical dysplasia, CD – cortical dysplasia.
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on genotype–phenotype correlations. The ﬁrst MTOR
group consisted of patients with FCDIIa and intractable
seizures who carried mutations in either position 1460
(Leu to Pro) or 2215 (Ser to Phe or Tyr). The second
MTOR group presented correlations with a Thr1997Ile
mutation. These patients were characterized by asym-
metric megalencephaly with polymicrogyria. Two of three
patients displayed seizures. The third MTOR group had
diﬀuse megalencephaly and carried a Glu1799Lys amino
acid substitution. An analysis of the eﬀects of the MTOR
mutation on mTORC1 activity showed that the most and
least active mutants correlated with FCDIIa and megalen
cephaly/hemimegalencephaly, respectively.
Additional insights into the role of mTOR in MCD have
come from recent animal models. Lim et al. (2015) used in
utero electroporation to introduce mTOR(Leu2427Pro) to
cortical neuroprogenitors. This resulted in the appearance
of electroporated cytomegalic neurons in the cortex and
spontaneous seizures 3 weeks after birth. Animals that
developed seizures were then given rapamycin, which
resulted in seizure cessation and the shrinkage of cell
bodies of electroporated neurons. The eﬀectiveness of
rapamycin in treating the FCDII-like phenotype was also
conﬁrmed in another study, in which Bordey and col-
leagues (Hsieh et al., 2016) developed a new experimen-
tal model of FCDII. They employed in utero
electroporation to introduce constitutively active Rheb
(RhebCA) speciﬁcally to the medial prefrontal cortex. By
2 months of age, these mice developed several charac-
teristic features of FCD2, including cell mispositioning,
white matter heterotopia, the appearance of dysmorphic
neurons with greater mTORC1 activity, astrogliosis, and
most importantly severe seizures. When RhebCA was
introduced to the somatosensory cortex, the animals
developed no seizures, suggesting that pathological
changes need to occur in a particular brain area. Another
important observation of this study was that postnatal
rapamycin treatment prevented changes in both FCDcortical architecture and seizure development. Rapamy-
cin discontinuation resulted in recurrent seizures in more
than 50% of the mice, although cortical lamination
remained intact. These observations corroborate the ﬁnd-
ings of some TSC models, in which mTOR hyperactivity-
related seizures may occur in the absence of cortical
malformations. The results also indicate the necessity of
lifelong rapamycin treatment in mTOR hyperactivity-
related epilepsies.
Neuroﬁbromatosis. Neuroﬁbromatosis type I (NF1) is
a relatively common neurocutaneous syndrome that
occurs in 1 in 2,500 in the general population. It is
characterized by the development of benign and
malignant tumors of the central and peripheral nervous
systems and abnormalities in the skin, bones, and
kidneys. Many patients also suﬀer from learning
disabilities, ADHD, and anxiety (Johannessen et al.,
2005; Diggs-Andrews and Gutmann, 2013). Some
patients develop epilepsy, although this is relatively rare.
NF1 is caused by mutations in the gene that encodes
neuroﬁbromin 1, which acts as a GTPase-activating pro-
tein for the protooncogene Ras, suppressing its activity
(Fig. 4). Consequently, cells with mutations in NF1 have
high levels of activation of the mitogen-activated protein
kinase and PI3K pathways (Lau et al., 2000). Subse-
quently, mutations in NF1 were shown to increase the
activation of mTORC1 in human samples of NF1-
associated pilocytic astrocytomas and neuroﬁbromatosis
1 patients’ malignant peripheral nerve sheath tumor
(MPNST) cells cultured in vitro (Dasgupta et al., 2005;
Johannessen et al., 2005). In the latter case, rapamycin
treatment eﬀectively reduced rpS6 phosphorylation and
the rate of cell proliferation. A causal link between upreg-
ulation of the mTORC1 pathway and the partial or com-
plete loss of Nf1 was further conﬁrmed in various cell
cultures and animal models. One of the intriguing obser-
vations was that Nf1 KO-dependent mTORC1 activation
in cultured astrocytes required Akt but not TSC2 or Rheb
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increase in the proliferation of Nf1/ astrocytes
depended on Akt but not Rheb. According to
Johannessen et al. (2005), the activation of mTORC1 in
Nf1/ mouse embryonic ﬁbroblasts (MEFs) required
Tsc2. The reasons for this discrepancy are not clear
because diﬀerent models were used, and the molecular
mechanisms that underlie Tsc2/Rheb-independent regu-
lation in astrocytes are not fully understood.
As in the case of Tsc1, Tsc2, and Pten, several mouse
models that involve heterozygous, mosaic, or conditional
loss of Nf1 have been developed (Table A.1).
Heterozygous Nf1+/ mice did not develop tumors of
the nervous system that are speciﬁc to NF1 patients.
Cichowski et al. (1999) developed two new mouse mod-
els, Nf1+/+:Nf1/ chimeric mice and Nf1+/:p53+/
mutants, that develop neuroﬁbromas and MPNST,
respectively. The latter model was used to demonstrate
an increase in mTORC1 activation in MPNST cells and
the eﬀectiveness of rapamycin in inhibiting the growth of
this highly malignant tumor and consequently prolonging
mouse survival (Johannessen et al., 2008). However,
similar to the case of the several models described so
far, the tumor regrew after rapamycin discontinuation.
The beneﬁcial eﬀects of mTOR inhibition were also evi-
dent in Nf1ﬂ/ﬂ;GFAP-Cre mice, which developed optic
glioma (Hegedus et al., 2008; Banerjee et al., 2011b).
However, recent studies suggest that not only mTORC1
contributes to glioma formation in NF1. Using an NSC
proliferation assay, Lee et al. (2010) showed that the loss
of Nf1 increases the proliferation of NSCs in the brain-
stem but not neocortex. This was attributed to the higher
expression of Rictor in Nf1/ NSCs in the brainstem than
in the neocortex and the subsequent activation of
mTORC2-Akt and degradation of p27, a cyclin-
dependent kinase inhibitor. Clinical trials have evaluated
mTOR inhibitors for the treatment of neuroﬁbromas in
NF1 patients. In contrast to TSC, mTOR inhibitors did
not exert any clear beneﬁcial eﬀects on the clinical symp-
toms of NF1.Fragile X syndrome. Fragile X syndrome (FXS) is a
leading genetic cause of inherited mental retardation in
males and relatively frequent cause of autism.
Additional neurological FXS symptoms include
hyperactivity, sleep problems, epileptic seizures, and
anxiety. One cause for the disease is trinucleotide
(CGG) repeat expansion in the 50 untranslated region of
the fragile X mental retardation gene. The fully
developed phenotype occurs once the number of
repeats reaches 200. The consequence of this mutation
is the loss of FMRP (fragile X protein), an RNA-binding
protein that is involved in the translational silencing of
mRNAs to be locally translated in dendrites and
postsynaptic sites. The loss of FMRP expression
subsequently leads to aberrant increases in the
translation of several proteins, several of which
contribute to synaptic and structural plasticity (e.g.,
GluA2, PSD95, RhoA, Rac1, and matrix
metalloproteinase 9; Ferna´ndez et al., 2013). Postmortem
analyses of patients’ brain samples revealed severalabnormalities in neuronal morphology, including substan-
tial changes in dendritic spine shape (Irwin et al., 2001).
The excessive translation of mRNAs that are typically
bound by FMRP is considered a molecular cause of FXS.
The potential contribution of mTOR to FXS pathology and
therapeutically targeting mTORC1 have been considered.
Fragile X-related mTOR activation was ﬁrst described in
KO mice (Sharma et al., 2010; Bhattacharya et al.,
2012; Amiri et al., 2014). Subsequently, Hoeﬀer et al.
(2012) showed that mTOR pathway activity is upregu-
lated in both patient-derived lymphocytes and brain tissue
from FXS patients. Joint work by the Zukin and Klann lab-
oratories showed that KO of the FMRP-encoding gene
disinhibited PIKE-L, an upstream activator of the PI3K-
Akt-mTORC1 pathway (Fig. 4). However, in this study,
the short-term application of rapamycin, similar to the pro-
tein synthesis inhibitor anisomycin, failed to inhibit the
increase in mGluR-driven LTD, which is a hallmark of
FXS (Sharma et al., 2010). This argues against the
involvement of mTORC1 in this FXS-related synaptic
pathology. One consideration, however, is that protein
synthesis is already saturated in this FXS model, and
the relatively short-term inhibition of de novo protein syn-
thesis may be insuﬃcient to reverse FXS-related synaptic
defects. This hypothesis was corroborated by the obser-
vation that the lack of S6K1 in FXS KO mice, which leads
to long-term eﬀects on translation, reversed synaptic,
dendritic spine, and behavioral defects that were caused
by the lack of FMRP (Bhattacharya et al., 2012).
Down syndrome. Down syndrome is the most
common chromosomopathy in humans. It is caused by
the presence of an additional, third copy of chromosome
21 (or a part of the chromosome). The disease is
characterized by several neurological abnormalities, the
most common of which is intellectual disability. Down
syndrome patients can also suﬀer from autism and have
a higher risk of epilepsy, including infantile spasm. Older
Down syndrome patients (40 years of age) develop
symptoms of Alzheimer’s disease and have a high risk
of stroke. Two independent studies revealed greater
activation of the mTORC1 pathway in brain tissue from
Down syndrome patients (Iyer et al., 2014; Perluigi
et al., 2014). mTORC1 hyperactivity appeared early in
development and steadily increased until adulthood.
Perluigi et al. (2014) observed an increase in mTOR activ-
ity in Down syndrome patients both with and without Alz-
heimer’s disease pathology. Iyer et al. (2014) observed
very strong activation of mTORC1 in cells with character-
istic Alzheimer’s disease features (e.g., neuroﬁbrillary tan-
gles), suggesting that increased mTORC1 activity to
some extent contributes to the neurodegeneration that
is observed in Down syndrome patients, similar to Alzhei-
mer’s disease (see below). However, studies with mTOR
inhibitors in animal models of Down syndrome are needed
to further conﬁrm the causal role of mTOR in this disease.
Neurodegenerative disorders
Major neurodegenerative disorders (e.g., Huntington’s
disease, Parkinson’s disease, and Alzheimer’s disease),
non-Alzheimer tauopathies, spinocerebral ataxia type 3,
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are characterized by the accumulation of syndrome-
speciﬁc protein aggregates. The involvement of mTOR
in the control of both translation and autophagy
prompted several research teams to investigate mTOR
activity and the therapeutic potential of rapamycin in
various animal models (e.g., in mice, rats, and
Drosophila; Bove et al., 2011; Lipton and Sahin, 2014;
Bockaert and Marin, 2015). Indeed, increased mTORC1
activation was reported in patients with Alzheimer’s dis-
ease (An et al., 2003; Li et al., 2005; Tramutola et al.,
2015). Moreover, rapamycin treatment or the partial
genetic reduction of mTOR levels improved learning and
memory deﬁcits in diﬀerent models of Alzheimer’s dis-
ease (Caccamo et al., 2010, 2014; Spilman et al.,
2010). Beneﬁcial eﬀects of mTOR inhibition with rapalogs
(e.g., a reduction of cell death and improvements in
behavioral deﬁcits) were observed in most studies that
involved animal models of other neurodegenerative disor-
ders (Bove et al., 2011; Lipton and Sahin, 2014; Bockaert
and Marin, 2015). Nevertheless, the inhibition of
mTORC1 might not always be beneﬁcial as a treatment
option for neurodegenerative disorders. For example, in
mice with a G93A mutation in SOD1, which serves as a
model of amyotrophic lateral sclerosis, rapamycin accel-
erated motor neuron degeneration and shortened the ani-
mals’ lifespan (Zhang et al., 2011).Non-syndromic/cryptogenic epilepsy
As mentioned above, several genetic disorders show a
strong causal link between mTORC1 activation and
epilepsy. Several animal models of temporal lobe
epilepsy (TLE) establish a more general role for
mTORC1 in epileptogenesis. Strong mTORC1 activation
in the brain was reported immediately upon KA- or
pilocarpine-induced status epilepticus and during
subsequent days when epileptogenesis occurred
(Buckmaster et al., 2009; Zeng et al., 2009; Hartman
et al., 2012; Sha et al., 2012; Macias et al., 2013;
Shima et al., 2015). Acute pentylenetetrazol-induced sei-
zures result in immediate but transient mTORC1 activa-
tion (Zhang and Wong, 2012). mTORC1-induced
increases in signaling were described in epilepsy that
was evoked by electric stimulation of the amygdala and
angular bundle (Sliwa et al., 2012; van Vliet et al.,
2012). mTOR activation was observed in both neuronal
cells and glia but at diﬀerent times post-status epilepticus.
Macias et al. (2013) showed that after KA treatment, neu-
ronal mTORC1 activation preceded astrocytic activation
by several hours. Shima et al. (2015) reported a second
wave of mTORC1 activation in dentate gyrus neurons
but as late as 21 days after KA application. Sha et al.
(2012) reported mTORC1 activation in astrocytes and
oligodendrocytes at later timepoints post-KA in already
pathologically altered hippocampi.
Although mTOR is generally accepted to be activated
in various models of TLE, unknown are the speciﬁc
processes associated with epileptogenesis that actually
require mTOR (e.g., seizure severity, neuronal cell
death, neurogenesis, astrogliosis, axonal sprouting ofdentate gyrus cells, dispersion of dentate gyrus granular
neurons, synaptogenesis, blood–brain barrier leakage,
and behavioral changes). The most beneﬁcial eﬀects of
mTOR inhibition were described in KA-induced epilepsy.
In a pioneering study by Zeng et al. (2009), prolonged
rapamycin treatment post-KA eﬃciently inhibited KA-
induced cell death, neurogenesis, axonal sprouting, and
spontaneous seizure development. Other groups
reported less signiﬁcant eﬀects of rapamycin treatment
that was administered post-KA. For example, Shima
et al. (2015) reported the eﬀects of rapamycin on dentate
gyrus cell dispersion, mossy ﬁber sprouting, and
astrogliosis but no eﬀects on the inhibition of cell death
or spontaneous seizure development. As opposed to
rapamycin treatment during epileptogenesis, many stud-
ies reported no beneﬁts or even adverse eﬀects of rapa-
mycin treatment prior to KA administration. Six-hour or
3-day pretreatment had no eﬀect on the severity of KA-
induced status epilepticus in mice (Hartman et al.,
2012). One-week rapamycin pretreatment shortened the
seizure onset time and increased the number of rats that
exhibited status epilepticus in the KA model (Macias
et al., 2013). Four-week pretreatment additionally
increased mortality upon KA administration (Macias
et al., 2013).
In a pilocarpine model, rapamycin treatment after the
epileptogenic stimulus appeared to impact seizure-
induced anatomical changes. Similar to the KA model,
rapamycin inhibited mossy ﬁber sprouting (Buckmaster
et al., 2009; Buckmaster and Lew, 2011; Tang et al.,
2012; Hester et al., 2016). The inhibitory eﬀects of rapa-
mycin on excitatory synapse formation on proximal den-
drites in dentate gyrus granule neurons were recently
reported (Yamawaki et al., 2015). The beneﬁcial eﬀects
of rapamycin were also demonstrated with regard to mod-
erating aggressive behavior that stemmed from
pilocarpine-induced epilepsy. However, similar to the KA
model, there is disagreement about whether mTORC1
inhibition suppresses both anatomical changes and recur-
rent seizures or only the former (Buckmaster and Lew,
2011; Tang et al., 2012).
With regard to models of TLE that is induced by
electrical stimulation, rapamycin treatment after
epileptogenic stimulation of the angular bundle inhibited
recurrent seizures and reduced blood–brain barrier
leakage in rats (van Vliet et al., 2012; Drion et al.,
2016). Drug pretreatment was ineﬀective in preventing
seizure development under this protocol (Drion et al.,
2016). Rapamycin posttreatment was ineﬀective in mod-
els of amygdala electrostimulation (Sliwa et al., 2012).
Directly comparing the aforementioned studies is diﬃcult
because they used diﬀerent seizure induction protocols,
rapamycin doses, application regimens, animal species,
and ages. However, the studies have some commonali-
ties: (i) rapamycin pretreatment did not prevent status
epilepticus, and (ii) rapamycin posttreatment was eﬀec-
tive only when continuously applied. Similar to the mod-
els of genetic disorders described above, the
discontinuation of rapamycin treatment resulted in the
reappearance of seizures and aberrant sprouting
(Buckmaster et al., 2009; Drion et al., 2016). These
128 K. Switon et al. / Neuroscience 341 (2017) 112–153diﬀerences matter only when mTOR is hyperactivated in
humans with TLE. Two studies have been published to
date in this regard. mTORC1 activation in the sclerotic
hippocampus was conﬁrmed by these studies, but it
occurred primarily in astrocytes and more rarely in neu-
ronal cells of the dentate gyrus (Sha et al., 2012;
Sosunov et al., 2012). Thus, mTOR also appears to be
activated in TLE patients and animal models of TLE,
although the degree to which mTOR contributes to
TLE remains to be determined.MOLECULAR BASIS OF MTOR-RELATED
NEUROPATHOLOGIES
Protein translation
Because of the important role of mTOR in protein
synthesis, dysregulated translation has been considered
a major molecular cause of several of the diseases
discussed above. Mental retardation and autism that are
associated with TSC, FXS, and Down syndrome were
believed to stem from an increase in either global or
local translation. Indeed, increased global translation
was reported in neurons in Fmr1/ mice, and this
particular phenotype was corrected by S6K1 knockout,
similar to morphological, electrophysiological, and
behavioral deﬁcits (Bhattacharya et al., 2012). In Ts1Cje
mice, a mouse model of Down syndrome, a substantial
increase in synaptic translation that was caused by the
excessive release of BDNF was found to be mTOR-
dependent (Troca-Marı´n et al., 2011). FMRP and BDNF
control the local synthesis of important neuronal
plasticity-related proteins, suggesting that the excessive
translation of synaptic proteins in mental retardation syn-
dromes leads to the dysregulation of neuronal responses.
However, some recent ﬁndings suggest selective rather
than global upregulation of protein synthesis as a source
of the problems with neuronal communication in mental
retardation and autism. For example, Gkogkas et al.
(2013) developed new animal models of ASD by knocking
out 4e-bp2 or overexpressing eif4E. They found high
selectivity in translation upregulation. Among the tested
proteins, only the translation of neuroligin 1 was upregu-
lated, and Nlgn1 knockdown was suﬃcient to correct
the autistic phenotype. Another protein, PARK7, was
recently found to be upregulated at synapses of Tsc1-
lacking neurons in vivo. PARK7 is involved in various cel-
lular processes, including transcriptional regulation,
mRNA binding, and the stress response (Niere et al.,
2016). Although the function of PARK7 at the synapse
remains unknown, its greater abundance is potentially
common to TSC, ASD, and Alzheimer’s disease (Niere
et al., 2016). However, the links between translation and
mental retardation and autism appear to be more com-
plex. Although some behavioral phenotypes are almost
indistinguishable between Fmr1/y, 4e-bp2/, and
Tsc2+/ mice, the latter ones exhibit decreases in global
protein synthesis, regardless of whether mTORC1 activity
is increased (Auerbach et al., 2011). Among the proteins
that were decreased in Tsc2+/ animals was Arc, a key
synaptic plasticity protein that is involved in regulatingAMPAR traﬃcking (Bramham et al., 2010; Auerbach
et al., 2011). Global translational proﬁling in neurons with
Tsc2 knockdown also revealed that neurons that lacked
Tsc2 exhibited downregulation of the translation of some
synaptogenesis genes (e.g., Snap91 and Cbln1; Nie
et al., 2015). The translation of 65 mRNAs, several of
which are known to encode parts of the stress response
(e.g., Atf3 and Ucp2), was upregulated. Rapamycin cor-
rected the association of only 28 of these mRNAs with
ribosomes (Nie et al., 2015). Thus, dysregulation of the
translation of a particular group of proteins, rather than
global upregulation of protein synthesis, appears to be
linked to mental retardation and ASD symptoms.
In addition to neurodevelopmental diseases, aberrant
mTOR-driven translation was postulated to contribute to
neurodegenerative disorders. Early work by the Pei
group revealed a correlation between increased
activation of the mTOR pathway and mTOR-related
translational machinery and the accumulation of Tau
protein (An et al., 2003; Li et al., 2005). In Huntington’s dis-
ease, the mTOR-dependent translation of mutated hunt-
ingtin may partially contribute to the increase in mutated
protein aggregation, at least in ﬁbroblasts (King et al.,
2008). In models of Parkinson’s disease, the mTORC1-
dependent upregulation of RTP801 translation leads to
dopaminergic neuron death (Malagelada et al., 2006,
2010). RTP801 is an inhibitor of prosurvival mTORC2-
Akt signaling, and mTORC1 inhibition by rapamycin is
beneﬁcial for cell survival (Malagelada et al., 2010). Dro-
sophila models of Parkinson’s disease also indicate the
dysregulation of mTOR-dependent translation through
4E-BP1 hyperphosphorylation (Tain et al., 2009). A recent
study of mTOR hyperactivation in Leigh syndrome pro-
vided an additional mechanism by which increases in glo-
bal translation challenge neurons with dysfunctional
mitochondria (e.g., in Parkinson’s disease). Zheng et al.
(2016) showed that a decrease in the oxidative production
of ATP resulted in the accumulation of amino acids, subse-
quent mTOR hyperactivation, and increased translation,
which increases the consumption of the remaining ATP,
thus making neurons more vulnerable to toxic challenges
(e.g., by glutamate).
Finally, in a model of opioid-induced tolerance (i.e.,
repeated morphine injections), protein synthesis and
eiF4A–eiF4E binding increased and were reversed by
rapamycin (Xu et al., 2014). Both rapamycin treatment
and mTOR knockdown in the spinal cord prevented the
development and maintenance of opioid tolerance and
related hyperalgesia (Xu et al., 2014). These observa-
tions led to the hypothesis of a potential role for aber-
rant increases in mTOR-dependent translation in
chronic pain and hyperalgesia, in which mTOR is acti-
vated by NMDA and opioid receptors, respectively
(Lutz et al., 2015).
Autophagy. Several studies have tested whether
mTOR-dependent autophagy contributes to
neurodegeneration. The beneﬁts of rapamycin
treatment in the context of autophagy induction and
aggregate clearance were described in several studies
that used models of Alzheimer’s disease and
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Spilman et al., 2010; Bove et al., 2011; Siman et al.,
2015). In mouse and Drosophila models of Huntington’s
disease, mTOR inhibition induced autophagy and ame-
liorated the toxicity associated with huntingtin aggre-
gates (Ravikumar et al., 2004). These aggregates
were also cleared in a neuronal cell model after treat-
ment with catalytic mTORC1 and mTORC2 inhibitors
(Roscic et al., 2011). Protein aggregate clearance via
the mTORC1 pathway was shown to occur in cases of
other polyglutamine and polyalanine aggregate-prone
proteins, including ataxin-1, ataxin-3, and tau (Berger
et al., 2006). The clearance of a-synuclein aggregates
upon mTORC1 inhibition was also found in animal and
cellular models of Parkinson’s disease (Crews et al.,
2010). Interestingly, the enhancement of autophagy by
mTOR inhibition was also beneﬁcial in these Parkin-
son’s disease models, in which a-synuclein aggregates
were not a major and immediate cause of pathology
(Bove et al., 2011). One of the potential targets is mito-
chondria, which are often damaged in Parkinson’s dis-
ease because of oxidative stress. Increases in
mitophagy prevented mitochondria-related proapoptotic
signaling (e.g., cytochrome C release; Bove et al.,
2011).
The dysregulation of mTOR-dependent autophagy
also appears to participate in mTORopathies that
are related to neuroplasticity. Increases in Ulk1
phosphorylation and decreases in autophagy were
reported in Tsc1ﬂ/ﬂ;CamKIIa-Cre and Ptenﬂ/ﬂ;CamKIIa-
Cre KO mice (McMahon et al., 2012). Mice that lack
Atg7 (Atg7ﬂ/ﬂ;CamKIIa-Cre), a key protein for autophagy
initiation, also develop spontaneous seizures. One
hypothesis is that the inhibition of autophagy through
mTOR upregulation might contribute to epileptogenesis
(McMahon et al., 2012). This hypothesis, however, awaits
further testing to demonstrate a causal link and targets of
autophagy during this process. Tang et al. (2014) recently
suggested a contribution of autophagy inhibition to ASD
and TSC. They observed diminished dendritic spine prun-
ing in the brains of ASD patients. Further analyses
showed that these deﬁcits were accompanied by fewer
autophagic vesicles and enhanced mTOR activity in neu-
rons. These observations were supported by experiments
in a TSC mouse model (Tang et al., 2014).
Autophagy may also be altered in brain tumors that
accompany TSC. An analysis of TSC patient brain
biopsies clearly showed a substantial increase in Ulk1
phosphorylation and the accumulation of p62 (i.e., an
indication of autophagic ﬂux blockade) in cortical tubers
and SEGAs (McMahon et al., 2012; Yasin et al., 2013;
Di Nardo et al., 2014). The extent to which autophagy
inhibition contributes to this tumor formation remains to
be established (Switon et al., 2016).Transcription and other cellular processes. Much
attention has been paid to the role of protein
translation and autophagy in mTORopathies, but the
contributions of other processes that are regulated by
mTOR to neuropathology are comparatively less
understood. One of these may be transcription. Thereis evidence of profound mTOR-dependent
transcriptome changes in mTORopathies, the most
comprehensive studies of which have been on TSC.
For example, transcriptomes of Tsc2/, Tsc2/+, and
Tsc2+/+ murine neuroepithelial cells were compared.
Signiﬁcant ﬁvefold diﬀerences in the expression of 67
genes were found between wildtype and Tsc2-null
cells. Analyses of these genes revealed a reduction
of the expression of neuronal markers and the
upregulation of genes that encode the cytoskeleton
and adhesion and cell signaling proteins (Onda et al.,
2002). This study also analyzed diﬀerences in the
expression of 59 genes that are relevant to neuronal
development, tuber formation, and epileptogenesis
between giant cells and wildtype neurons. Twenty-
seven of these genes were diﬀerentially expressed.
Increased expression was observed for transcripts that
encode subunits of neurotransmitter receptors, whereas
decreases were observed for those that encode sev-
eral trophic factor receptors (e.g., TrkB, PDGFRa,
and PDGFRb). Tyburczy et al. (2010) compared
SEGAs from patients with control tissue. Similar to
the study by the Kwiatkowski group, the expression
of genes that are involved in neuronal development
was downregulated, and genes that are linked to
tumorigenesis were upregulated. Comparisons of
untreated SEGA-derived lines with rapamycin-treated
lines showed that the expression proﬁles of some
genes could be reversed by rapamycin (e.g., ANXA1,
GPNMB, LTF, RND3, S100A11, SFRP4, and NPTX1).
The analysis of transcript abundance in TSC models
was not restricted to only undiﬀerentiated or tumor
cells. The Sahin group showed that Tsc2 knockdown
in neurons that were cultured in vitro resulted in strong
upregulation of several transcripts that are involved in
unfolded protein and oxidative cellular responses, and
such increases were prevented by rapamycin treatment
(Di Nardo et al., 2009; Nie et al., 2015). Similar
changes were reported in the brains of P30 mice with
Tsc1 KO that was induced on E18 (Goto et al., 2011).
Recent studies suggested that the stress-induced
upregulation of Atf3 and its target genes (e.g., gelsolin)
may contribute to dendritic spine changes that are
observed in TSC (Nie et al., 2015). Notably, however,
these examples do not necessarily prove that mTOR
directly participates in transcription regulation in TSC.
Increases in mTOR activity may increase cellular stress
through an imbalance in protein production and degra-
dation, which in turn triggers a transcriptional response.
Furthermore, Bateup et al. (2013) found that the major-
ity of transcriptional changes that are observed in
‘‘TSC model neurons” derive from a chronic increase
in network activity, which is secondary to Tsc1 loss.
Thus, more work is needed to distinguish the primary
vs. secondary eﬀects of mTOR on transcriptional
responses in TSC.
mTOR-dependent changes in the transcriptome were
also reported in models of Parkinson’s disease,
Alzheimer’s disease, epilepsy, glioblastoma, and
retinitis pigmentosa (Rieker et al., 2011; Caccamo
et al., 2014; Wu et al., 2014; Blazejczyk et al., 2016).
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mTOR in mouse models of Parkinson’s disease leads to
the inhibition of TIF-1A and YY-1 transcription factors
and subsequent nucleolar disruption and a lower stress
response, respectively. The amyloid precursor protein
mouse model of Alzheimer’s disease exhibits substantial
changes in the transcriptome. The removal of one copy
of mTOR rescued the expression of over 200 transcripts
to normal levels (e.g., Ulk1, Ncam1, and dynactin 1).
However, this study did not evaluate the signiﬁcance of
these changes in ameliorating neuropathological symp-
toms. With regard to epilepsy, our recent data (dis-
cussed above) show that mTORC1 inhibition changes
the expression proﬁles of Elmo1, Abra, Gprc5a, and
Gadd45g in response to KA-induced status epilepticus
(Blazejczyk et al., 2016). In the case of glioblastoma,
recent studies suggest that the upregulation of mTORC2
activity may contribute to the metabolic reprogramming
of tumor cells. mTORC2-driven changes in the transcrip-
tion of genes that are involved in glycolytic, lipid,
glutamine, and reactive oxygen species metabolism
are ‘‘suspected,” with postulations of the involvement
of c-Myc and SREBP1 as downstream mTORC2 eﬀec-
tors (Wu et al., 2014). Finally, the mTOR–Hif1a-depen
dent transcription of genes that are involved in cell meta-
bolism (e.g., Glut1, PK-M2, G6PD, heksokinase HK2,
and ME1) was hypothesized to explain the prosurvival
eﬀects of insulin and trophic factors on photoreceptors
in mouse models of retinitis pigmentosa (Venkatesh
et al., 2015).
Finally, when discussing the potential contributions of
mTOR to neuropathology, additional processes beyond
translation, autophagy, and transcription may also be
dysregulated and contribute to overall disease outcome.
Among these are the feedback inhibition of receptor
tyrosine kinase activity via the mTOR or S6K1
phosphorylation of receptor accessory proteins,
disturbances in intracellular transport and the cell
surface expression of glucose transporters, and
lysosomal biogenesis/autoreformation (Malik et al.,
2013b). Although these processes appear to be disturbed
in diseases that are characterized by changes in mTOR
activity, their direct dependence on mTOR and contribu-
tion to pathology have not been thoroughly studied.CONCLUSIONS
Research over last few years has revealed enormous
complexity of the mTOR signaling network in
mammalian cells. This knowledge has just begun to
change neuroscientists’ perspectives on the contribution
of mTOR to its numerous eﬀects during neuronal
development and physiology. This substantial signaling
complexity upstream and downstream of mTOR
expands the potential clinical interventions that can be
tailored for particular diseases or even speciﬁc
symptoms of a disease. Further research that links
disturbances in mTOR-controlled processes and
neuropathology is needed before reaching this stage.COMPETING INTERESTS
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APPENDIX A
Table A.1. Animal models of selected mTOR-related diseases
Animal model Expected range of
genetic
modiﬁcation
Phenotype mTOR inhibition eﬀects Ref.
Biochemical/Cellular neuroanatomical Physiological/behavioral
TSC1/2
Tsc1+/ Global one Tsc1
allele KO
GluN2B, GluN2C/D
function"
Not analyzed Epilepsy (P9–18) Not analyzed Lozovaya et al. (2014)
Tsc1+/ Global one Tsc1
allele KO
No changes in spine
density and dendritic
branching
No cerebral lesions;
No giant dysmorphic
neurons
No epilepsy (adult);
Impaired hippocampus
depending learning;
Impaired social behavior
Not analyzed Goorden et al. (2007)
Tsc2+/ Global one Tsc2
allele KO
P-S6(S235/236)",
Hip3
Not analyzed No epilepsy (adult);
Impaired hippocampus
depending learning;
Lowered threshold for L-LTP
induction
Rapamycin (5 mg/kg or
1 mg/kg, daily for 5 days):
P-S6;;
Learning deﬁcits;;
L-LTP induction threshold
"
Ehninger et al. (2008)
Tsc1ﬂ/ﬂ;CamKIIa-
Cre
Tsc1 KO in mature
forebrain neurons
P-S6(240/244)";
neuronal cell size"
Brain size";
astrogliosis"
Lifespan;;
KA-induced seizure severity";
KA-induced death"
pathological hindlimb clasping
reﬂex;
Hypoactivity
Rapamycin (0.2 mg/kg
daily starting P1):
Lifespan";
brain size";
Hindlimb clasping reﬂex;;
activity"
Ehninger et al. (2008),
Bateup et al. (2013)
Tsc2+/ Global one Tsc2
allele KO
Global protein
synthesis;;
Arc synthesis;
Not analyzed mGluR LTD deﬁcits;
no context discrimination
Rapamycin (acute):
Restoration of mGluR-LTD
in slices
Auerbach et al. (2011)
Tsc2+/ Global one Tsc2
allele KO
P-S6 (S235/236)",
retinal ganglion cells
Defects in ipsilateral
retinogeniculate
projections
Not analyzed in vivo Not analyzed in vivo Nie et al. (2010)
Tsc2+/ Global one Tsc2
allele KO
Not analyzed not analyzed Impaired social mother-pup
interactions
Not analyzed Young et al. (2010)
Tsc2+/; Tsc2ﬂ/ﬂ;
CamKIIa-Cre
Global one Tsc2
allele KO; Tsc2 KO
in mature forebrain
neurons
Dendritic spine
density";
Spine pruning,
cortical pyramidal
neurons"
Not analyzed Impaired in novel object
recognition;
Impaired social interactions
(tested only for Tsc2+/)
Rapamycin (3 mg/kg/day
from P21 to P28):
Dendritic spine pruning"
Tang et al. (2014)
Tsc2ﬂ/ﬂ;CamKIIa-
Cre
Tsc2 KO in mature
forebrain neurons
P-S6(240/244)", Hip Not analyzed Lifespan;*
*Extended by daily glutamine
supplementation
Not analyzed Rozas et al. (2015)
(continued on next page)
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Table A.1 (continued)
Animal model Expected range of
genetic
modiﬁcation
Phenotype mTOR inhibition eﬀects Ref.
Biochemical/Cellular neuroanatomical Physiological/behavioral
Tsc1+/ Tsc2+/ Global one Tsc1 or
Tsc2 allele KO
P-S6K1(T389)";
Tsc1, Gsk3b, Ulk1,
Erk2, Eef2k mRNA
(tested only for
Tsc2+/)"
Not analyzed Impaired social interaction Rapamycin (2, 5 and
10 mg/kg once daily for 2
consecutive days):
P-S6K1;;
Tsc1, Gsk3b, Ulk1, Erk2,
Eef2k mRNA;;
Social interaction
improvement
Sato et al. (2012)
Tsc1/ﬂ;SynI-Cre Second copy Tsc1
KO in Tsc1
heterozygous
neurons starting
E12.5
P-S6(S235/236)";
Cell soma size";
Improper axonal
orientation;
spine density;
Lamination defects, Cx;
Enlarged ectopic cells,
Hip;
Dysplastic neurons
hypomyelination
Lifespan;
Body mass;;
Clasping;
Tremor
Rapamycin and RAD001
(both 6 mg/kg every 2nd
day starting P7–9):
Lifespan";
Body mass";
Clasping;;
tremor;;
Neuronal cell size ; (but no
eﬀects on dysplastic
features);
Myelination"
Meikle et al. (2007,
2008), Di Nardo et al.
(2009)
Tsc1ﬂ/ﬂ;GFAP-Cre
(Tsc1GFAP1CKO)
Tsc1 KO in
astrocytes (not
veriﬁed in radial
glia)
P-S61, Hip, Cx ";
Expression of Glt-1;2
Glutamate levels, Hip";
Neuronal cell death, Hip";
Astrocyte proliferation";
astrogliosis";
Brain size";
Hip size";
Disorganization of layers;
No cortical tubers
Lifespan;;
Epilepsy; impaired
hippocampal LTP;
Impaired hippocampus-
dependent learning
Rapamycin (3 mg/kg, 5
days/week for 5 weeks
starting at P14):
P-S6;;
Astrogliosis;; brain size ;;
Hip size;;
Hippocampal
disorganization;;
Lifespan";
Epilepsy;;
Rapamycin (3 mg/kg, 5
days/week for 5 weeks
starting at P60 for 3 weeks;
after seizure onset):
Epilepsy;;
Lifespan"
Uhlmann et al. (2002),
Zeng et al. (2008)
Tsc2ﬂ/ﬂ;GFAP-Cre
(Tsc2GFAP1CKO)
Tsc2 KO in
astrocytes (not
veriﬁed in radial
glia)
P-S61, Hip, Cx "*;
Glt-1 expression;*
*More severe than in
Tsc1GFAP1CKO
Brain size";
Astrocyte proliferation";
Astrogliosis";
Lamination defects, Hip*
Lifespan;;
Epilepsy
Rapamycin (3 mg/kg, 5
days/week for 5 weeks
starting at P14):
P-S6;;
Zeng et al. (2011)
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*More severe than in
Tsc1GFAP1CKO
Astrocyte proliferation;;
Disorganization of
hippocampus;;
Lifespan";
Epilepsy;
Tsc1ﬂ/ﬂ;hGFAP-
Cre
(Tsc2GFAP2CKO)
Tsc1/ﬂ;hGFAP-
Cre
Tsc1 KO in radial
glia
P-S6(S235/236),
Cx";
P-Akt(S473);;
P-Stat(S727)";
Neuronal cell soma
size";
Disarranged
projections of Cx
pyramidal neurons
Brain size";
Cortical thickness";
Lamination defects, Hip,
Cx;
Presences of ectopic
neurons;
Hypomyelination;
Number of astrocytes";
Lateral ventricles size";
SVZ expansion;
SEN-like lesions
Lifespan;;
Epilepsy
Rapamycin (6 mg/kg every
2 days starting P8):
Epilepsy;;
P-S6;;
Cortical thickness;;
Astrogliosis;;
Size of lateral ventricles;;
SVZ expansion;;
SEN-like lesions;
Magri et al. (2013)
Tsc2ﬂ/ﬂ;hGFAP-Cre
(Tsc2GFAP2CKO)
Tsc2 KO in radial
glia
P-S6, Pax6 positive
cells, neurons,
astrocytes";
Cell soma size,
neurons and
astrocytes"
Brain size";
Lamination defects, Hip,
Cx;
Heterotopias;
Astrogliosis";
Hypomyelination
Body weight; Not analyzed Way et al. (2009)
Tsc1/ﬂ;GFAP-
Cre,
Tsc2/ﬂ;GFAP-
Cre,
Tsc1/ﬂ;GFAP-
Cre
x
Tsc2/ﬂ;GFAP-
Cre
Single or double
Tsc1 and Tsc2 KO
in radial glia
P-S6(S235/236;
S240/244)"*;
P-Akt(S473);*;
neuronal cell size,
Cx"*
*No diﬀerence
between single and
double mutants
Cortical thickness"*;
Ectopic Cux-positive
neurons in lower cortical
layers*;
Number of early born
neurons in cortical layer
IV;*;
Lamination defects, Hip**;
Ring heterotopias, Hip***;
Astrogliosis"*;
Number of mature
oligodendrocytes;*;
Hypomyelination**Similar
in all 3 mutants
**Subtle diﬀerences
between mutants
***Only in Tsc2 and
double mutants
Lifespan;*;
Body mass;
*Double mutant life span
signiﬁcantly shorter
Not analyzed Mietzsch et al. (2013)
Tsc1ﬂ/ﬂ;Dlx5/6-Cre Tsc1 KO in GABA-
(Magri et al. (2011;
Carson et al. (2012)
ergic neurons
P-S61 ";
Cell size, GABAergic
neurons, Hip, Cx,"
Number of CR and NPY
positive GABAergic
neurons, Cx;
Body weight;;
Lifespan;;
Sensitivity to ﬂurothyl-induced
seizures"
Not analyzed Fu et al. (2012)
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Table A.1 (continued)
Animal model Expected range of
genetic
modiﬁcation
Phenotype mTOR inhibition eﬀects Ref.
Biochemical/Cellular neuroanatomical Physiological/behavioral
Tsc2ﬂ/ﬂ;Nex-Cre Tsc2 KO in early
postmitotic
excitatory neurons
in embryonic
forebrain
P-S6 (S235/236)";
P-Akt (S473, T308);;
No. of axons/cell";
Dendritic branching"
Cell dispersion, Cx, Hip;
Astrogliosis"
Body weight;;
Lifespan;
RAD001 (10 mg/kg daily
starting P1):
Lifespan";
P-S6 (S235/236)";
P-Akt (S473, T308);;
Astrogliosis;
Crowell et al. (2015)
Tsc1ﬂ/ﬂ;Nestin-Cre Tsc1 KO in neural
stem cells during
early development
P-S6 (S235, S240)";
Cell size, Cx"
Brain size";
Cell density, Cx layers IV
and V, ;
Astrogliosis"
Normal layer formation,
Cx
Lifespan;
(due to impaired maternal pup
interaction)
Rapamycin (single dose
1 mg/kg given to pregnant
mouse) :
Pup survival";
P-S6;;
Cell density";
No change in cell size
Additional rapamycin
(gradually increasing
doses [1 to 3 mg/kg]
starting P8):
lifespan";
P-S6;;
P-Akt"
Anderl et al. (2011)
Tsc2F36-37ﬂ/ﬂ;
Emx1-Cre
Selective KO of
GAP domain of
TSC2 in neural
progenitor cells
giving rise to
cortical neurons
P-S6 (S240/244), Cx,
";
P-4EBP (T37/46), Cx,
"
Not analyzed Lifespan;;
Body mass;
Rapamycin (0,1 mg/kg/day
postnatally):
Lifespan";
Body mass"
Fu and Ess (2013)
Tsc1ﬂ/ﬂ;Emx1-Cre
Tsc1/ﬂ;Emx-
Cre
Tsc1 KO in
embryonic NCSs of
wild type mice or
second Tsc1 allele
KO in embryonic
NCSs of Tsc1
heterozygous mice
P-S6 (S235/236)";
P-ERK";
P-Akt (S473);;
neuronal cell size"
Brain size";
Cortical thickness";
Hydrocephaly;
Displastic and ectopic
neurons, Cx;
Ring heterotopias;
Astrogliosis";
Hypomyelination;
Expanded and
disorganized
hippocampal regions;
Lamination defects, Cx;
Disorganization of
postnatal SVZ niche;
Tumor-like lesions in
Lifespan;;
Lower body mass;;
Epilepsy
Rapamycin (6 mg/kg every
2 days starting P8):
P-S6;;
Body mass";
Lifespan";
Epilepsy;;
Astrogliosis;;
Hypomyelination;;
Cortical thickness;;
Hydrocephalus;;
Rapamycin (3 mg/kg, 5
days/week for 4 weeks
starting at P15):
P-S6;;
Astrogliosis;;
Magri et al. (2011),
Carson et al. (2012)
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ventricles;
Migration defects along
RMS
Brain size;;
Epilepsy;;
Lifespan";
Tumor like lesions;
Tsc1ﬂ/ﬂ;L7-Cre Tsc1 knockout in
Purkinje cells (PCs)
P-S61";
Neuronal cell size";
spine density";
Aberrant axonal
sprouting;
Cleaved caspase 3";
ER stress";
Oxidative stress"
Number of PC cells; Excitability of PC cells;;
Autistic like behaviors";
Ataxic behaviors"
Rapamycin (6 mg/kg,3
times a week starting P7):
PC cell survival";
Autistic like behaviors;;
Ataxic behaviors;
Tsai et al. (2012)
Tsc2ﬂ/ﬂ;Pcp2-Cre Tsc2 knockout in
Purkinje cells (PC,
starting P6)
P-S6(S240/244)";
neuronal cell size";
ER stress";
Oxidative stress"
Number of PC cells; Motor functions; Rapamycin (2 mg/kg,
3x week, starting P10):
Neuronal cell size;;
PC cell survival";
ER stress;;
Motor functions"
Reith et al. (2011)
Tsc2ﬂ/ﬂ;Olig2-Cre Tsc2 KO in
oligodendrocite
precursors
P-S6(240/244)";
P-NDRG1;;
MBP, CNP;
Hypomyelination; axon
density;;
Oligodendrocite
number;;
Astrogliosis, Cx and white
matter"
No signiﬁcant deﬁcits in motor,
anxiety and social behavior
Rapamycin (0.1 mg/kg,
P3–17; P30–60):
Myelination"
Carson et al. (2015)
Tsc1ﬂ/ﬂ;Gbx2-
CreERT
Tamoxifen-induced
Tsc1 KO in
thalamic neurons
(E12 and 18)
P-S6(240/244)";
Neuronal cell size";
Membrane input
resistance (E12
KO);;
input capacitance
(E12 KO)"
Altered thalamocortical
projections
Abnormal neural activity (local
ﬁeld potentials in cortex);
Overgrooming;
Epilepsy (E12 KO)
Not analyzed Normand et al. (2013)
Tsc1ﬂ/ﬂ;Lhx2-Cre Tsc1 KO in eye
committed neural
progenitor cells
P-S6 (S235/236;
S240/244) in eye
cells"
Eye size",
Retinal folding;
Loss of ora serrata
integrity;
Heterotopias and
hamartomas;
Astrogliosis";
Changes in optic nerve
morphology;
Aberrant retinogeniculate
topography
Not analyzed Not analyzed Jones et al. (2015)
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Table A.1 (continued)
Animal model Expected range of
genetic
modiﬁcation
Phenotype mTOR inhibition eﬀects Ref.
Biochemical/Cellular neuroanatomical Physiological/behavioral
Tsc2cdel3/ﬂ;Syn1-
Cre
(Tsc2cc)
Tsc2/
cdel3;Syn1-Cre
(Tsc2kc)
Graded reduction
of Tsc2 activity in
neurons due to
introduction of
either two
hypomorphic Tsc2
alleles (Tsc2cc) or
one null, one
hypomorphic
(Tsc2kc)
P-S6(S235/236) ";
neuronal cell size";
*Proportional to the
extent of Tsc2 loss
Number of ectopic
neurons in the
hippocampus"
Lifespan;*;
Locomotor activity"; anxiety;*;
Impaired social interaction
*Proportional to the extent of
Tsc2 loss
Not analyzed Yuan et al. (2012)
Tsc1ﬂ/ﬂxNestin-
rtTAxTRE-Cre
Dox given at E8,
E10, E13, E16–
17
doxycycline
induced mosaic
Tsc1 KO in diﬀerent
brain areas; E8
small proportion of
cells thalamus,
brain stem, spinal
cord; E10
widespread
recombination in all
brain areas, E16
restricted KO in
cortex,
hippocampus and
cerebellum
E13 dox:
P-S6 (S235,S 240),
neurons, glia, ",
mTORC2 activity,
neurons, glia;,
Dysmorphic neurons
with increased cell
size;
Nucleus size";
complexity of basal
dendrites, Cx,";
Aberrant orientation
of apical dendrite;
ER stress";
Inﬂammatory
response";
Vacuolated giant cells
with immature
lysosomes and
mitochondrial
expansion
E8 dox:
Degeneration of white
matter in a spinal cord
E13 dox:
Brain size";
Astrogliosis";
Hypomyelination;
Vacuolated giant cells,
Cx
All dox:
Lifespan;;
E13 dox:
Hyperactivity;
Epilepsy
Rapamycin (starting P8):
Lifespan;;
Epilepsy of E13 dox mice;;
mTORC1 activity;;
astrogliosis;;
ER stress and
inﬂammation;;
Partial correction of
improper apical dendrite
polarity
Goto et al. (2011)
Tsc1ﬂ/ﬂ;Nestin-
CreERT2
Tamoxifen induced
Tsc1 KO in neural
stem cells (P7 or
P30)
Giant cells with
increased P-S61
within tumor mass;
NeuN expression in
DCX positive
neuroblasts
Brain size";
Hydrocephalus;
Nodular protrusions on
lateral ventricle walls
(SEN-like);
Small tumors near
intraventricular foramen
(SEGA-like);
Not analyzed Not analyzed Zhou et al. (2011)
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No. of granule neurons in
OB (due to decreased
migration);
Tsc1ﬂ/ﬂ;AsclI-
CreERTM
Tamoxifen induced
Tsc1 selectively in
transit amplifying
cells of SVZ
Not analyzed No gross brain
abnormalities;
Hydrocephalus in some
cases;
SEN- and SEGA-like
abnormalities
Not analyzed Not analyzed Zhou et al. (2011)
Tsc1ﬂ/ﬂ;Cag-
CreERT
Tamoxifen induced
Tsc1 KO in adult
mice
P-S6 (235/236)" No hypomyelination;
no astrogliosis
L-LTP threshold;; excitability";
epilepsy;
Seizure induced lethality
Rapamycin (10 mg/kg post
seizures):
Epilepsy;
Abs et al. (2013)
Tsc1ﬂ/ﬂ;Nestin-
CreERT2
Tamoxifen induced
postnatal Tsc1 KO
in neural stem cells
(P7)
Not analyzed SEGA-like lesions, SVZ;
lesions in RMS;
mutated cell mistargeted
to cortex.
Not analyzed Not analyzed Feliciano et al. (2012)
Tsc1ﬂ/ﬂ+ AAV-Cre
injection to CA1
Tsc1 KO in infected
CA1 neurons
P-S6(S240/244)";
Intrinsic excitability;
Not analyzed Inhibitory transmission;;
Excitatory-inhibitory synaptic
imbalance
Rapamycin (5 mg/kg, 7
days prior to experiment):
Correction of excitatory-
inhibitory synaptic
imbalance
Bateup et al. (2013)
Tsc1ﬂ/+Cre
electroporation
(Epo)
Second Tsc1 allele
KO in
electroporated
neural stem cells
(E15–16)
P-S6(240/244)";
Neuronal soma size";
Multinucleated
neurons
E16 Epo, P15:
Heterotopic nodules with
enlarged neurons, Cx;
E15 Epo, P15:
Tuber like lesions, Cx
Threshold for PTZ-induced
seizures;
Not analyzed Feliciano et al. (2011)
Tsc1ﬂ/+Cre
electroporation
@ P0–1
Postnatal second
Tsc1 allele KO in
SVZ neural stem
cells
P-S6(240/244)";
Increased HIF1a
expression";
Neuronal cell size";
Nuclei size";
Increased size and
more complex
morphology of cells in
RMS;
Hypertrophy of OB
neuron dendritic
arbors
Heterotopias in and
outside RMS consisting
of neuronal or neuroglial
cells;
Neuronal micronodules in
OB;
Mutated cell mistargeted
to cortex
Not analyzed Not analyzed Feliciano et al. (2012,
2013)
Tsc2 shRNA in
utero
electroporation
Embryonic Tsc2
knockdown in
neural stem cells
(E14)
P-S6 (S235/236)";
Neuronal cell size"
Lamination defects, Cx Not analyzed Fetal rapamycin (5 mg/kg):
Neuronal cell volume;;
Lamination defects;
Tsai et al. (2014)
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Table A.1 (continued)
Animal model Expected range of
genetic
modiﬁcation
Phenotype mTOR inhibition eﬀects Ref.
Biochemical/Cellular neuroanatomical Physiological/behavioral
Tsc1ﬂ/ﬂ +AAV-
Cre
Tsc1 KO in
transduced
neurons (viral
injection at P0)
P-S6 (S235/236)";
Neuronal cell size"
Brain size";
Mild hydrocephalus;
Nodules and thickening
of the ventricular lining
Lifespan; Not analyzed Prabhakar et al.
(2013)
DRG mice Global
overexpression of
dominant negative
Tsc2
Not analyzed in brain
tissue
Aggregates of granular
cells at the cerebellum
surface
Anxiety";
Impaired social behavior
Impaired motor learning
Not analyzed Govindarajan et al.
(2005), Ehninger and
Silva (2011), Che´vere-
Torres et al. (2012)
Tsc2 shRNA
postnatal
electroporation
(Wistar rats)
Postnatal Tsc2
knockdown in
neural stem cells of
SVZ (P0)
P-S6(235/236)";
Neuroblast cell size,
RMS"
Not analyzed Not analyzed Not analyzed Malik et al. (2015b)
PTEN
Pten+/ Global one Pten
allele KO
Not analyzed Not analyzed Aggression;;
Repetitive behavior"
Not analyzed Clipperton-Allen and
Page (2014, 2015)
Ptenﬂ/ﬂ;GFAP-Cre
(NS-Pten)
Pten KO in granular
neurons of DG and
cerebellum
P-S6(S235/236), P-
Akt(S473), Cb, Hip":
Neuronal cell size,
DG, Cb
PCs atrophy;
Dysplastic neurons, Cb
Lifespan;;
Epilepsy
CCI-779 (10–50 mg/kg, 5
days a week for 4–
8 weeks):
P-S6;;
Neuronal cell size, DG;;
Lifespan";
Epilepsy;
Kwon et al. (2001,
2003)
Ptenﬂ/ﬂ;GFAP-Cre
(NS-Pten)
Pten KO reported
also for cortical
neurons
P-S6(S240/244),";
Neuronal cell size,
Cx"
Brain size";
Aberrant mossy ﬁber
sprouting
Epilepsy Rapamycin (10 mg/kg 5
days a week, for 2 weeks
starting at week 4):
P-S6;*;
Neuronal cell size;*;
Mossy ﬁber sprouting;*;
Epilepsy;*;
*only up to 5 weeks post
rapamycin);
Repeated rapamycin
2 week rapamycin
treatments (weeks 4–5,
10–12, 16–18):
Extension of seizure free
period;
Lifespan"
Ljungberg et al.
(2009), Sunnen et al.
(2011)
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Ptenﬂ/ﬂ;GFAP-Cre
(NS-Pten)
As above P-S6(240/244)";
P-Akt(S473)"
Astrogliosis",
Microgliosis"
lifespan;;
epilepsy
Rapamycin (10 mg/kg 5
days a week, starting at
postnatal week 9):
P-S6;;
P-Akt;;
GFAP;;
IBA1;;
Established epilepsy;;
Lifespan"
Nguyen et al. (2015)
Ptenﬂ/ﬂ;GFAP-Cre
(NS-Pten)
As above P-S6(240/244),
S6K1, P-Akt(S473),
FMRP, P-FMRP
(S499), Hip,"
Not analyzed Trace and contextual memory
impairment
Not analyzed Lugo et al. (2013)
Ptenﬂ/ﬂ;hGFAP-Cre Pten KO in
astrocytes and
subset of neurons.
KO observed also
in some
oligodendrocites
P-Akt(S473)";
Neuron and astrocyte
cells size";
Increased astrocyte
proliferation";
Neuronal ribosome
density";
nucleoli size";
increased spine
density";
Pre-synaptic
terminals size";
Postsynaptic
densities extending
past the pre-synaptic
terminal
Brain size";
Myelination "
LTP, CA3-CA1; Not analyzed Fraser et al. (2004,
2008)
Ptenﬂ/ﬂ;hGFAP-Cre Pten KO in radial
glia
P-Akt, GFAP, DCX";
NR2B, PSD95;;
Prolonged
proliferation of radial
glia
Brain size";
Gliosis;
Hyperplasia;
Hydrocephalus;
Impaired lamination, Hip,
Cb;
Number of neuronal
progenitors";
Not analyzed Not analyzed Wen et al. (2013)
Ptenﬂ/ﬂ;DAT-Cre Pten KO in
dopaminergic
neurons
DA neuron cell size" Not analyzed Impaired social interaction Not analyzed Clipperton-Allen and
Page (2014)
Ptenﬂ/ﬂ;Nse-Cre Pten KO in a subset
of postmitotic
Neuron cell size, DG,
Cx";
Brain size";
Cell dispersion, DG
Impaired social interaction and
learning;
Rapamycin (10 mg/kg daily
for 5 days a week):
Kwon et al. (2006),
Ogawa et al. (2007),
(continued on next page)
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Table A.1 (continued)
Animal model Expected range of
genetic
modiﬁcation
Phenotype mTOR inhibition eﬀects Ref.
Biochemical/Cellular neuroanatomical Physiological/behavioral
neurons of cortex
and hippocampus;
(max. Cre
expression  P30)
Dendritic caliber,
DG,";
Ectopic dendrites,
DG;
Spine density"
Dysregulation of theta burst
induced LTP and mGluR-
dependent LTD, medial
perforant path-to-dentate gyrus
synapses of young mice;
Epilepsy
Neuron ell size;;
Dendri caliber;;
Brain s e;;
Behav al deﬁcits;;
Eﬀects f rapamycin on
LTP an LTD not tested
Zhou et al. (2009),
Takeuchi et al. (2013)
Pten+/ﬂ;Emx1-Cre,
Ptenﬂ/ﬂ;Emx1-
Cre
Pten KO in neural
progenitor cells of
the developing
forebrain
P-Akt (S473), P-
GSK3 (S9)"*,
P-S6
(235/236)"***both
hetero- and
homozygous Pten KO
**only homozygous
Pten KO
Brain mass"*;
Cerebral cortex mass"*;
Cell number"**;
*Partly mTOR dependent
**mTOR independent
Not analyzed Rptor+ does not prevent
eﬀects f Pten
haploin ﬁciency
Chen et al. (2015)
Ptenﬂ/ﬂ;En2-Cre Pten KO in
developing
cerebellum cells
P-Akt (S473),
dysplastic neurons
and glia";
Cell size of all
precursor cells and
their progeny"
Cerebellum size;
Lack of lamination;
Dysplastic neurons and
astrocytes;
PCs death
Ataxia;
Impaired balance;
Activity;
Not an zed Marino et al. (2002)
Ptenﬂ/ﬂ;L7-Cre Pten KO in PCs P-Akt (S473), PCs";
PCs cell size";
dendrites and axons
caliber"
PCs death (after 17–
20 weeks of age)
Not analyzed Not an zed Marino et al. (2002)
Ptenﬂ/ﬂ;Gli1-
CreERT2
Pten KO only in a
subset of
postnatally
generated neurons
(DG and OB)
P-S61";
DG neurons size";
Number of apical
dendrites";
Presence of basal
dendrites,
spine density"
Ectopic neurons in DG;
Mossy ﬁber sprouting
Lifespan;;
Epilepsy
Rapam in (6 mg/kg
daily/5 ays a week
starting 14):
P-S6;,
epileps ;
mossy er sprouting;
Pun et al. (2012)
Ptenﬂ/ﬂ;Nestin-
CreERT2
Pten KO induced in
neural stem cells/
progenitors
(tamoxifen injection
on P0–1, P11–12
or P28–30)
P-S6(S235/236)";
Premature cell
diﬀerentiation
SVZ size";
Diameter of terminal
RMS";
Density of granule
neurons, OB;
Not analyzed Rapam in (as described
in Kwo et al. (2003);
3 days rior to tamoxifen):
SVZ e ansion;
Zhu et al. (2012)
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Ptenﬂ/ﬂ;Nestin-
CreERT2
Pten KO induced in
neural stem cells/
progenitors by
(tamoxifen injection
at 4 weeks of age)
P-S6(S235/236), P-
Akt(S473), P-GSK3b
(S9)";
Cell size";
Dendrite number and
length";
Abnormal neuron
polarity;
Accelerated
diﬀerentiation of
neuronal progenitor
cells
Lamination defects, DG
granular cell layer
Impaired social interaction;
Infrequent epilepsy
Not analyzed Amiri et al. (2012)
Ptenﬂ/ﬂ;Nex-Cre Pten KO in early
postmitotic
excitatory neurons
in embryonic
forebrain
P-S6(S240/244), P-
Akt(T308, S473)";
MAP2, NR2A,
NR2B";
neuron soma size";
Brain size" Lifespan;;
Body mass;
Rapamycin (0.5 mg/kg
subcutaneous
Injections every other day,
2 weeks starting at P1):
Lifespan";
Body mass"
Kazdoba et al. (2012)
Ptenﬂ/ﬂ;Rip-Cre Pten KO in
hypothalamus
not analyzed No analyzed Postnatal growth;;
Serum insulin levels;;
Blood glucose levels;
Not analyzed Choi et al. (2008)
Ptenﬂ/ﬂ;Dmbx1-Cre Pten KO in
midbrain
Not analyzed Hydrocephalus Lifespan; Not analyzed Ohtoshi (2008)
Lv-shPTEN Pten knockdown in
neonatal and young
adult mice DG
Neonatal and young
adult:
Cell soma size";
Axons and dendrite
caliber";
Spine density";
Input resistance;;
mEPSC freq.";Young
adults:
frequency of
spontaneous
EPSCs";
mEPSC freq. and
amplitude"
Not analyzed Not analyzed Not analyzed Luikart et al. (2011)
Ptenﬂ/ﬂ +RetroV-
Cre
Pten KO only in
neural stem cells of
DG
P-S6(S235/236), P-
Akt (S473), P-GSK3b
(S9)";
c-Fos";
Neuron soma size";
Basal
electrophysiological
Aberrant neuronal
migration, DG granular
cell layer
Rapamycin (10 mg/kg,
daily, 3–14 dpi, 14–24 dpi):
P-S6;;
Neuron soma size";
Migration defects
prevention (but not
reversal);
Williams et al. (2015),
Getz et al. (2016)
(continued on next page)
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Table A.1 (continued)
Animal model Expected range of
genetic
modiﬁcation
Phenotype mTOR inhibition eﬀects Ref.
Biochemical/Cellular neuroanatomical Physiological/behavioral
properties alteration;
Excitability";
Dendritic arbors
complexity";
spine density"
Eﬀects on electrical
properties and dendritic
morphology not analyzed
NF1
Nf1+/, Nf1ﬂ/ﬂ;
GFAP-Cre,
Nf1/ﬂ;GFAP-
Cre
Nf1ﬂ/ﬂ;GFAP-Cre:
Nf1 KO in
astrocytes starting
E14
Nf1/ﬂ;GFAP-Cre:
global single Nf1
allele KO (E0),
second Nf1 allele
KO selectively in
astrocytes (E14)
Nf1/GFAP:Cre:
number of P-S6
positive cells in
tumor-bearing mice"
Nf1ﬂ/ﬂ;GFAP-Cre:
astrocyte proliferation"
Nf1/ﬂ;GFAP-Cre:
Optic nerve gliomas
Not analyzed Nf1/ﬂ;GFAP-Cre:
Rapamycin (5 or 20 mg/kg
daily): P-S6;;
Tumor proliferation;
Bajenaru et al. (2002,
2003), Dasgupta et al.
(2005), Hegedus et al.
(2008)
Nf1ﬂ/
Nf1ﬂ/ﬂ;SynI-Cre
Nf1ﬂ/:
global one Nf1
allele KO
Nf1ﬂ/ﬂ;SynI-Cre:
Nf1 KO in neurons
Nf1ﬂ/ﬂ;SynI-Cre:
P-ERK"
Nf1ﬂ/ﬂ;SynI-Cre:
Forebrain weight;;
Cerebral cortex
thickness;;
Cell density";
astrogliosis";
NO tumor development
Nf1ﬂ/:
Lifespan;
Nf1ﬂ/ﬂ;SynI-Cre: Growth
retardation starting P3–4
Not analyzed Zhu et al. (2001)
Nf1+/:p53+/
(NPcis mice)
Nf1 and p53 null
alleles in cis
P-S6(S235/236),
tumors";
Cyclin D1, tumors,"
Tumor development
(MPNSTs)
Lifespan; Rapamycin (5 mg/kg
starting at the time of tumor
detection, 5 days a week):
P-S6;;
Cyclin D1;;
Tumor growth;
Cichowski et al.,
(1999) and
Johannessen et al.
(2008)
FXR1
Fmr1/ Global Fmr1 KO P-S6 (S235/236;
S240/244), P-eiF4B";
Global protein
synthesis";
Expression of
PSD95, Shank3,
CamKIIa, eEF2"
Abnormal spine
morphology;
Spine density"
Hippocampal mGluR-LTD";
Impaired motor and social
behavior
Crossing Fmr1/ with
S6K1/:
Signaling abnormalities;;
Spine morphology
correction;
Spine density;
mGluR-LTD;;
Bhattacharaya et al.
(2012)
1
5
0
K
.
S
w
ito
n
e
t
a
l./N
e
u
ro
s
c
ie
n
c
e
3
4
1
(2
0
1
7
)
1
1
2
–
1
5
3
Behavioral deﬁcits;
Fmr1/ Global Fmr1 KO P-mTOR(S2448), P-
S6K1(T389), P-4E-
BP(Thr37/46)";
Raptor-mTOR
interaction";
eiF4G–eiF4E
interaction"*
*no upregulation by
DHPG
Not analyzed mGluR-LTD, Hip," Rapamycin (20 nM):
No eﬀect on enhanced
mGluR-LTD in acute slices
Sharma et al. (2014)
Fmr1ﬂ/ﬂ;Nse:Cre Fmr1 KO in mature
cortical and
hippocampal
neurons
VGLUT1, VGAT, Cx,
;;
P-S6K1(T389), P-Akt
(S473), P-GSK3b
(S9)";
Dendritic arbor
complexity, Hip CA3;
Changes is spine shape;
No global changes in
gross morphology;
No change in spine
density,
No eﬀect on tested behavior Not analyzed Amiri et al. (2014)
1Exact epitope not deﬁned by the authors.
2Astrocyte speciﬁc glutamate transporter.
3Hip – hippocampus, Cx – cortex, Cb – cerebellum, DG – dentate gyrus, NSCs – neural stem cells.
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